{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:13:16Z","timestamp":1790161996747,"version":"4.1.0"},"reference-count":314,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04385-7","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:25:52Z","timestamp":1778858752000},"page":"4389-4418","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Head and neck squamous cell carcinoma: current and emerging therapeutic strategies"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6943-4593","authenticated-orcid":false,"given":"Parul","family":"Ahuja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9202-770X","authenticated-orcid":false,"given":"Lokesh","family":"Kadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2890-9593","authenticated-orcid":false,"given":"Sandeep","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7686-2369","authenticated-orcid":false,"given":"Ritu","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"4385_CR1","doi-asserted-by":"publisher","first-page":"107327482311850","DOI":"10.1177\/10732748231185003","volume":"30","author":"K Afshari","year":"2023","unstructured":"Afshari K, Sohal KS. Potential alternative therapeutic modalities for management head and neck squamous cell carcinoma: a review. Cancer Control. 2023;30:10732748231185004. https:\/\/doi.org\/10.1177\/10732748231185003.","journal-title":"Cancer Control"},{"key":"4385_CR2","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/medsci11020042","volume":"11","author":"A Barsouk","year":"2023","unstructured":"Barsouk A, Aluru JS, Rawla P, Saginala K, Barsouk A. Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci. 2023;11:42. https:\/\/doi.org\/10.3390\/medsci11020042.","journal-title":"Med Sci"},{"key":"4385_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrc.2018.11","volume":"18","author":"CR Leemans","year":"2018","unstructured":"Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18:269\u201382. https:\/\/doi.org\/10.1038\/nrc.2018.11.","journal-title":"Nat Rev Cancer"},{"key":"4385_CR4","doi-asserted-by":"publisher","first-page":"e2045","DOI":"10.1002\/cnr2.2045","volume":"7","author":"SM Jayawickrama","year":"2024","unstructured":"Jayawickrama SM, Ranaweera PM, Pradeep RGGR, Jayasinghe YA, Senevirathna K, Hilmi AJ, et al. Developments and future prospects of personalized medicine in head and neck squamous cell carcinoma diagnoses and treatments. Cancer Rep (Hoboken). 2024;7:e2045. https:\/\/doi.org\/10.1002\/cnr2.2045.","journal-title":"Cancer Rep (Hoboken)"},{"key":"4385_CR5","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/1055-9965.EPI-08-0347","volume":"18","author":"M Hashibe","year":"2009","unstructured":"Hashibe M, Brennan P, Chuang S-C, Boccia S, Castellsague X, Chen C, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009;18:541\u201350. https:\/\/doi.org\/10.1158\/1055-9965.EPI-08-0347.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"4385_CR6","doi-asserted-by":"publisher","first-page":"80","DOI":"10.14740\/wjon1104w","volume":"9","author":"AK Dhull","year":"2018","unstructured":"Dhull AK, Atri R, Dhankhar R, Chauhan AK, Kaushal V. Major risk factors in head and neck cancer: a retrospective analysis of 12-year experiences. World J Oncol. 2018;9:80\u20134. https:\/\/doi.org\/10.14740\/wjon1104w.","journal-title":"World J Oncol"},{"key":"4385_CR7","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.3390\/jcm12093264","volume":"12","author":"L Nokovitch","year":"2023","unstructured":"Nokovitch L, Maquet C, Crampon F, Taihi I, Roussel L-M, Obongo R, et al. Oral cavity squamous cell carcinoma risk factors: state of the art. J Clin Med. 2023;12:3264. https:\/\/doi.org\/10.3390\/jcm12093264.","journal-title":"J Clin Med"},{"key":"4385_CR8","doi-asserted-by":"publisher","first-page":"153303382211505","DOI":"10.1177\/15330338221150559","volume":"22","author":"A Khadela","year":"2023","unstructured":"Khadela A, Shah Y, Mistry P, Bodiwala K, Cb A. Immunomodulatory therapy in head and neck squamous cell carcinoma: recent advances and clinical prospects. Technol Cancer Res Treat. 2023;22:15330338221150560. https:\/\/doi.org\/10.1177\/15330338221150559.","journal-title":"Technol Cancer Res Treat"},{"key":"4385_CR9","doi-asserted-by":"publisher","first-page":"e058392","DOI":"10.1136\/bmjopen-2021-058392","volume":"12","author":"A Gormley","year":"2022","unstructured":"Gormley A, Richards C, Spiga F, Gray E, Hooper J, Main B, et al. Metabolic disorders and the risk of head and neck cancer: a protocol for a systematic review and meta-analysis. BMJ Open. 2022;12:e058392. https:\/\/doi.org\/10.1136\/bmjopen-2021-058392.","journal-title":"BMJ Open"},{"key":"4385_CR10","doi-asserted-by":"publisher","first-page":"1404860","DOI":"10.3389\/fonc.2024.1404860","volume":"14","author":"PT Bradley","year":"2024","unstructured":"Bradley PT, Lee YK, Albutt A, Hardman J, Kellar I, Odo C, et al. Nomenclature of the symptoms of head and neck cancer: a systematic scoping review. Front Oncol. 2024;14:1404860. https:\/\/doi.org\/10.3389\/fonc.2024.1404860.","journal-title":"Front Oncol"},{"key":"4385_CR11","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"4385_CR12","doi-asserted-by":"publisher","first-page":"548","DOI":"10.3390\/cancers17030548","volume":"17","author":"M Wierzbicka","year":"2025","unstructured":"Wierzbicka M, Pietruszewska W, Maciejczyk A, Markowski J. Trends in incidence and mortality of head and neck cancer subsites among elderly patients: a population-based analysis. Cancers (Basel). 2025;17:548. https:\/\/doi.org\/10.3390\/cancers17030548.","journal-title":"Cancers (Basel)"},{"key":"4385_CR13","doi-asserted-by":"publisher","first-page":"104551","DOI":"10.1016\/j.oraloncology.2019.104551","volume":"102","author":"A Miranda-Filho","year":"2020","unstructured":"Miranda-Filho A, Bray F. Global patterns and trends in cancers of the lip, tongue and mouth. Oral Oncol. 2020;102:104551. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104551.","journal-title":"Oral Oncol"},{"key":"4385_CR14","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1002\/ijc.32871","volume":"147","author":"C Bosetti","year":"2020","unstructured":"Bosetti C, Carioli G, Santucci C, Bertuccio P, Gallus S, Garavello W, et al. Global trends in oral and pharyngeal cancer incidence and mortality. Int J Cancer. 2020;147:1040\u20139. https:\/\/doi.org\/10.1002\/ijc.32871.","journal-title":"Int J Cancer"},{"key":"4385_CR15","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.3332\/ecancer.2023.1603","volume":"17","author":"S Bagal","year":"2023","unstructured":"Bagal S, Budukh A, Thakur JS, Dora T, Qayyumi B, Khanna D, et al. Head and neck cancer burden in India: an analysis from published data of 37 population-based cancer registries. ecancermedicalscience. 2023;17:1603. https:\/\/doi.org\/10.3332\/ecancer.2023.1603.","journal-title":"ecancermedicalscience"},{"key":"4385_CR16","doi-asserted-by":"publisher","first-page":"1373821","DOI":"10.3389\/fonc.2024.1373821","volume":"14","author":"M Constantin","year":"2024","unstructured":"Constantin M, Chifiriuc MC, Bleotu C, Vrancianu CO, Cristian R-E, Bertesteanu SV, et al. Molecular pathways and targeted therapies in head and neck cancers pathogenesis. Front Oncol. 2024;14:1373821. https:\/\/doi.org\/10.3389\/fonc.2024.1373821.","journal-title":"Front Oncol"},{"issue":"5","key":"4385_CR17","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10147-016-1005-x","volume":"21","author":"D Sano","year":"2016","unstructured":"Sano D, Oridate N. The molecular mechanism of human papillomavirus-induced carcinogenesis in head and neck squamous cell carcinoma. Int J Clin Oncol. 2016;21(5):819\u201326. https:\/\/doi.org\/10.1007\/s10147-016-1005-x.","journal-title":"Int J Clin Oncol"},{"key":"4385_CR18","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","volume":"92","author":"ML Gillison","year":"2000","unstructured":"Gillison ML. Evidence for a causal association between Human Papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92:709\u201320. https:\/\/doi.org\/10.1093\/jnci\/92.9.709.","journal-title":"J Natl Cancer Inst"},{"key":"4385_CR19","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","volume":"26","author":"AK Chaturvedi","year":"2008","unstructured":"Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for Human Papillomavirus\u2013related and \u2013unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26:612\u20139. https:\/\/doi.org\/10.1200\/JCO.2007.14.1713.","journal-title":"J Clin Oncol"},{"key":"4385_CR20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1634\/theoncologist.2012-0200","volume":"18","author":"A Chu","year":"2013","unstructured":"Chu A, Genden E, Posner M, Sikora A. A patient-centered approach to counseling patients with head and neck cancer undergoing Human Papillomavirus testing: a clinician\u2019s guide. Oncologist. 2013;18:180\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2012-0200.","journal-title":"Oncologist"},{"key":"4385_CR21","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.2147\/CMAR.S379173","volume":"14","author":"M Pinkiewicz","year":"2022","unstructured":"Pinkiewicz M, Dorobisz K, Zato\u0144ski T. Human papillomavirus-associated head and neck cancers. Where are we now? A systematic review. CMAR. 2022;14:3313\u201324. https:\/\/doi.org\/10.2147\/CMAR.S379173.","journal-title":"CMAR"},{"key":"4385_CR22","doi-asserted-by":"publisher","first-page":"1273516","DOI":"10.3389\/fonc.2023.1273516","volume":"13","author":"M Constantin","year":"2023","unstructured":"Constantin M, Chifiriuc MC, Mihaescu G, Vrancianu CO, Dobre E-G, Cristian R-E, et al. Implications of oral dysbiosis and HPV infection in head and neck cancer: from molecular and cellular mechanisms to early diagnosis and therapy. Front Oncol. 2023;13:1273516. https:\/\/doi.org\/10.3389\/fonc.2023.1273516.","journal-title":"Front Oncol"},{"key":"4385_CR23","doi-asserted-by":"publisher","first-page":"e702","DOI":"10.1002\/mco2.702","volume":"5","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang N, Wen Y, Wen J. Head and neck cancer: pathogenesis and targeted therapy. MedComm. 2024;5:e702. https:\/\/doi.org\/10.1002\/mco2.702.","journal-title":"MedComm"},{"key":"4385_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4161\/cbt.9.1.10905","volume":"9","author":"JD Klein","year":"2010","unstructured":"Klein JD, Grandis JR. The molecular pathogenesis of head and neck cancer. Cancer Biol Ther. 2010;9:1\u20137. https:\/\/doi.org\/10.4161\/cbt.9.1.10905.","journal-title":"Cancer Biol Ther"},{"key":"4385_CR25","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1172\/JCI59889","volume":"122","author":"SM Rothenberg","year":"2012","unstructured":"Rothenberg SM, Ellisen LW. The molecular pathogenesis of head and neck squamous cell carcinoma. J Clin Invest. 2012;122:1951\u20137. https:\/\/doi.org\/10.1172\/JCI59889.","journal-title":"J Clin Invest"},{"key":"4385_CR26","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.3390\/ijms22052252","volume":"22","author":"S-H Chen","year":"2021","unstructured":"Chen S-H, Hsiao S-Y, Chang K-Y, Chang J-Y. New insights into oral squamous cell carcinoma: from clinical aspects to molecular tumorigenesis. Int J Mol Sci. 2021;22:2252. https:\/\/doi.org\/10.3390\/ijms22052252.","journal-title":"Int J Mol Sci"},{"key":"4385_CR27","first-page":"1","volume":"21","author":"L Dunn","year":"2015","unstructured":"Dunn L, Rudin CM. Head and neck squamous cell carcinogenesis: molecular and genetic alteration. UpToDate. 2015;21:1\u201311.","journal-title":"UpToDate"},{"key":"4385_CR28","doi-asserted-by":"publisher","first-page":"101426","DOI":"10.1016\/j.tranon.2022.101426","volume":"21","author":"B Goel","year":"2022","unstructured":"Goel B, Tiwari AK, Pandey RK, Singh AP, Kumar S, Sinha A, et al. Therapeutic approaches for the treatment of head and neck squamous cell carcinoma-an update on clinical trials. Transl Oncol. 2022;21:101426. https:\/\/doi.org\/10.1016\/j.tranon.2022.101426.","journal-title":"Transl Oncol"},{"key":"4385_CR29","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.3390\/cancers16203488","volume":"16","author":"AM Lee","year":"2024","unstructured":"Lee AM, Weaver AN, Acosta P, Harris L, Bowles DW. Review of current and future medical treatments in head and neck squamous cell carcinoma. Cancers. 2024;16:3488. https:\/\/doi.org\/10.3390\/cancers16203488.","journal-title":"Cancers"},{"key":"4385_CR30","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/cancers13205206","volume":"13","author":"SF Powell","year":"2021","unstructured":"Powell SF, Vu L, Spanos WC, Pyeon D. The key differences between Human Papillomavirus-positive and -negative head and neck cancers: biological and clinical implications. Cancers (Basel). 2021;13:5206. https:\/\/doi.org\/10.3390\/cancers13205206.","journal-title":"Cancers (Basel)"},{"key":"4385_CR31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/s12885-020-07297-z","volume":"20","author":"Y-G Lee","year":"2020","unstructured":"Lee Y-G, Kang EJ, Keam B, Choi J-H, Kim J-S, Park KU, et al. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). BMC Cancer. 2020;20:813. https:\/\/doi.org\/10.1186\/s12885-020-07297-z.","journal-title":"BMC Cancer"},{"key":"4385_CR32","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","volume":"6","author":"DE Johnson","year":"2020","unstructured":"Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6:92. https:\/\/doi.org\/10.1038\/s41572-020-00224-3.","journal-title":"Nat Rev Dis Primers"},{"key":"4385_CR33","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1001\/jamaoto.2020.3496","volume":"146","author":"CC Hansen","year":"2020","unstructured":"Hansen CC, Egleston B, Leachman BK, Churilla TM, DeMora L, Ebersole B, et al. Patterns of multidisciplinary care of head and neck squamous cell carcinoma in Medicare patients. JAMA Otolaryngol Head Neck Surg. 2020;146:1136\u201346. https:\/\/doi.org\/10.1001\/jamaoto.2020.3496.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"4385_CR34","first-page":"2478","volume":"7","author":"J Shang","year":"2014","unstructured":"Shang J, Gu J, Han Q, Xu Y, Yu X, Wang K. Chemoradiotherapy is superior to radiotherapy alone after surgery in advanced squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Int J Clin Exp Med. 2014;7:2478\u201387.","journal-title":"Int J Clin Exp Med"},{"key":"4385_CR35","doi-asserted-by":"publisher","first-page":"16545","DOI":"10.3390\/ijms242216545","volume":"24","author":"WJT Tan","year":"2023","unstructured":"Tan WJT, Vlajkovic SM. Molecular Characteristics of Cisplatin-Induced Ototoxicity and Therapeutic Interventions. Int J Mol Sci. 2023;24:16545. https:\/\/doi.org\/10.3390\/ijms242216545.","journal-title":"Int J Mol Sci"},{"key":"4385_CR36","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/toxics3030268","volume":"3","author":"A Callejo","year":"2015","unstructured":"Callejo A, Sed\u00f3-Cabez\u00f3n L, Juan ID, Llorens J. Cisplatin-induced ototoxicity: effects. Mech Protect Strat Toxic. 2015;3:268\u201393. https:\/\/doi.org\/10.3390\/toxics3030268.","journal-title":"Mech Protect Strat Toxic"},{"key":"4385_CR37","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.3390\/biomedicines11112887","volume":"11","author":"C-Y Hsieh","year":"2023","unstructured":"Hsieh C-Y, Lin C-C, Chang W-C. Taxanes in the treatment of head and neck squamous cell carcinoma. Biomedicines. 2023;11:2887. https:\/\/doi.org\/10.3390\/biomedicines11112887.","journal-title":"Biomedicines"},{"key":"4385_CR38","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.clon.2013.07.007","volume":"25","author":"M Teo","year":"2013","unstructured":"Teo M, Karakaya E, Young CA, Dyker KE, Coyle C, Sen M, et al. The efficacy of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil combined with cisplatin concurrent chemoradiotherapy for locally advanced head and neck squamous cell carcinoma: a matched pair analysis. Clin Oncol. 2013;25:647\u201353. https:\/\/doi.org\/10.1016\/j.clon.2013.07.007.","journal-title":"Clin Oncol"},{"key":"4385_CR39","doi-asserted-by":"publisher","first-page":"e70757","DOI":"10.7759\/cureus.70757","volume":"16","author":"R Yadav","year":"2024","unstructured":"Yadav R, Panchal H, Patel A, Parikh S, Shah K. Neoadjuvant chemotherapy for borderline resectable head and neck cancers: a comparative study of three-drug and two-drug regimens in a low- and middle-income country (LMIC) context. Cureus. 2024;16:e70757. https:\/\/doi.org\/10.7759\/cureus.70757.","journal-title":"Cureus"},{"key":"4385_CR40","doi-asserted-by":"publisher","first-page":"935","DOI":"10.3390\/ejihpe10040066","volume":"10","author":"M Hunter","year":"2020","unstructured":"Hunter M, Kellett J, Toohey K, D\u2019Cunha NM, Isbel S, Naumovski N. Toxicities caused by head and neck cancer treatments and their influence on the development of malnutrition: review of the literature. Eur J Investig Health Psychol Educ. 2020;10:935\u201349. https:\/\/doi.org\/10.3390\/ejihpe10040066.","journal-title":"Eur J Investig Health Psychol Educ"},{"key":"4385_CR41","unstructured":"Board PS and PCE. Oral Complications of Chemotherapy and Head\/Neck Radiation (PDQ\u00ae). PDQ Cancer Information Summaries [Internet], National Cancer Institute (US); 2016."},{"key":"4385_CR42","doi-asserted-by":"publisher","first-page":"9205","DOI":"10.3390\/curroncol30100665","volume":"30","author":"EM Lee","year":"2023","unstructured":"Lee EM, Jim\u00e9nez-Fonseca P, Gal\u00e1n-Moral R, Coca-Membribes S, Fern\u00e1ndez-Montes A, Sorribes E, et al. Toxicities and quality of life during cancer treatment in advanced solid tumors. Curr Oncol. 2023;30:9205\u201316. https:\/\/doi.org\/10.3390\/curroncol30100665.","journal-title":"Curr Oncol"},{"key":"4385_CR43","doi-asserted-by":"publisher","first-page":"e61173","DOI":"10.7759\/cureus.61173","volume":"16","author":"S Sharma","year":"2024","unstructured":"Sharma S, Kumar Upadhyay A, Prakash A, Singodia P, Ravi Kiran S, Shankar R. Treatment complications of head and neck cancers and rehabilitation measures: a narrative review. Cureus. 2024;16:e61173. https:\/\/doi.org\/10.7759\/cureus.61173.","journal-title":"Cureus"},{"key":"4385_CR44","first-page":"4151","volume":"10","author":"V Chiruvella","year":"2020","unstructured":"Chiruvella V, Annamaraju P, Guddati AK. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am J Cancer Res. 2020;10:4151\u201364.","journal-title":"Am J Cancer Res"},{"key":"4385_CR45","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/lio2.711","volume":"7","author":"P Ranta","year":"2022","unstructured":"Ranta P, Kyt\u00f6 E, Nissi L, Kinnunen I, Vahlberg T, Minn H, et al. Dysphagia, hypothyroidism, and osteoradionecrosis after radiation therapy for head and neck cancer. Laryngoscope Investig Otolaryngol. 2022;7:108\u201316. https:\/\/doi.org\/10.1002\/lio2.711.","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"4385_CR46","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.3390\/jcm12083025","volume":"12","author":"E Topkan","year":"2023","unstructured":"Topkan E, Kucuk A, Somay E, Yilmaz B, Pehlivan B, Selek U. Review of osteoradionecrosis of the jaw: radiotherapy modality, technique, and dose as risk factors. J Clin Med. 2023;12:3025. https:\/\/doi.org\/10.3390\/jcm12083025.","journal-title":"J Clin Med"},{"key":"4385_CR47","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/cncr.34823","volume":"129","author":"CT Haring","year":"2023","unstructured":"Haring CT, Kana LA, Dermody SM, Brummel C, McHugh JB, Casper KA, et al. Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. Cancer. 2023;129:2817\u201327. https:\/\/doi.org\/10.1002\/cncr.34823.","journal-title":"Cancer"},{"key":"4385_CR48","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.ejso.2019.04.002","volume":"45","author":"E Alabraba","year":"2019","unstructured":"Alabraba E, Joshi H, Bird N, Griffin R, Sturgess R, Stern N, et al. Increased multimodality treatment options has improved survival for hepatocellular carcinoma but poor survival for biliary tract cancers remains unchanged. Eur J Surg Oncol. 2019;45:1660\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2019.04.002.","journal-title":"Eur J Surg Oncol"},{"key":"4385_CR49","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.oraloncology.2013.09.008","volume":"50","author":"E Benson","year":"2014","unstructured":"Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral Oncol. 2014;50:565\u201374. https:\/\/doi.org\/10.1016\/j.oraloncology.2013.09.008.","journal-title":"Oral Oncol"},{"key":"4385_CR50","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.21037\/atm-20-2984","volume":"8","author":"MP Strohl","year":"2020","unstructured":"Strohl MP, Wai KC, Ha PK. De-intensification strategies in HPV-related oropharyngeal squamous cell carcinoma-a narrative review. Ann Transl Med. 2020;8:1601. https:\/\/doi.org\/10.21037\/atm-20-2984.","journal-title":"Ann Transl Med"},{"key":"4385_CR51","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1200\/jco-24-02755","volume":"43","author":"FC Holsinger","year":"2025","unstructured":"Holsinger FC, Ismaila N, Adkins DR, Barber BR, Burnette G, Fakhry C, et al. Transoral robotic surgery in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma: ASCO guideline. J Clin Oncol. 2025;43:1369\u201392. https:\/\/doi.org\/10.1200\/jco-24-02755.","journal-title":"J Clin Oncol"},{"key":"4385_CR52","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.3390\/jcm12134210","volume":"12","author":"I Brudasca","year":"2023","unstructured":"Brudasca I, Philouze P, Morini\u00e8re S, Lallemant B, Vergez S, Malard O, et al. Transoral laser microsurgery versus robot-assisted surgery for squamous cell carcinoma of the tongue base (oncological and functional results)-A retrospective GETTEC multicenter study. J Clin Med. 2023;12:4210. https:\/\/doi.org\/10.3390\/jcm12134210.","journal-title":"J Clin Med"},{"key":"4385_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.25289\/ml.2020.9.2.103","volume":"9","author":"AR Padalhin","year":"2020","unstructured":"Padalhin AR. Lasers and robots: recent developments in transoral laser and transoral robotic surgery. Med Lasers. 2020;9:103\u20139. https:\/\/doi.org\/10.25289\/ml.2020.9.2.103.","journal-title":"Med Lasers"},{"key":"4385_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12101014","volume":"12","author":"G Molteni","year":"2024","unstructured":"Molteni G, Bassani S, Arsie AE, Zampieri E, Mannelli G, Orlandi E, et al. Role of TORS as de-escalation strategy in HPV-related oropharyngeal cancer, what we need to know. Healthcare (Basel). 2024;12:1014. https:\/\/doi.org\/10.3390\/healthcare12101014.","journal-title":"Healthcare (Basel)"},{"key":"4385_CR55","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-6203.103602","volume":"37","author":"T Gupta","year":"2012","unstructured":"Gupta T, Narayan CA. Image-guided radiation therapy: physician\u2019s perspectives. J Med Phys. 2012;37:174\u201382. https:\/\/doi.org\/10.4103\/0971-6203.103602.","journal-title":"J Med Phys"},{"key":"4385_CR56","doi-asserted-by":"publisher","first-page":"1175578","DOI":"10.3389\/fonc.2023.1175578","volume":"13","author":"AM Chen","year":"2023","unstructured":"Chen AM. De-escalated radiation for human papillomavirus virus-related oropharyngeal cancer: evolving paradigms and future strategies. Front Oncol. 2023;13:1175578. https:\/\/doi.org\/10.3389\/fonc.2023.1175578.","journal-title":"Front Oncol"},{"key":"4385_CR57","doi-asserted-by":"publisher","first-page":"153303382412585","DOI":"10.1177\/15330338241258596","volume":"23","author":"K Lang","year":"2024","unstructured":"Lang K, Held T, Freudlsperger C, Plath K, Hoffmann J, Plinkert PK, et al. Oral cavity squamous cell carcinoma: impact of clear margin distance on locoregional control in patients undergoing postoperative radiotherapy. Technol Cancer Res Treat. 2024;23:15330338241258596. https:\/\/doi.org\/10.1177\/15330338241258596.","journal-title":"Technol Cancer Res Treat"},{"key":"4385_CR58","unstructured":"Oral Cavity (Mouth) Cancer Treatment Options, by Stage n.d. https:\/\/www.cancer.org\/cancer\/types\/oral-cavity-and-oropharyngeal-cancer\/treating\/oral-cavity-options-by-stage.html (accessed March 30, 2026)."},{"key":"4385_CR59","unstructured":"PDQ Adult Treatment Editorial Board. Oropharyngeal Cancer Treatment (PDQ\u00ae): Health Professional Version. PDQ Cancer Information Summaries, Bethesda (MD): National Cancer Institute (US); 2002."},{"key":"4385_CR60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3322\/caac.21293","volume":"65","author":"AC Chi","year":"2015","unstructured":"Chi AC, Day TA, Neville BW. Oral cavity and oropharyngeal squamous cell carcinoma\u2014an update. CA Cancer J Clin. 2015;65:401\u201321. https:\/\/doi.org\/10.3322\/caac.21293.","journal-title":"CA Cancer J Clin"},{"key":"4385_CR61","unstructured":"Oropharyngeal (Throat) Cancer Treatment Options, by Stage n.d. https:\/\/www.cancer.org\/cancer\/types\/oral-cavity-and-oropharyngeal-cancer\/treating\/oropharyngeal-options-by-stage.html (accessed March 30, 2026)."},{"key":"4385_CR62","doi-asserted-by":"publisher","first-page":"3494","DOI":"10.1245\/s10434-017-6041-x","volume":"24","author":"RS Jackson","year":"2017","unstructured":"Jackson RS, Sinha P, Zenga J, Kallogjeri D, Suko J, Martin E, et al. Transoral resection of human papillomavirus (HPV)-positive squamous cell carcinoma of the oropharynx: outcomes with and without adjuvant therapy. Ann Surg Oncol. 2017;24:3494\u2013501. https:\/\/doi.org\/10.1245\/s10434-017-6041-x.","journal-title":"Ann Surg Oncol"},{"key":"4385_CR63","doi-asserted-by":"publisher","first-page":"4515","DOI":"10.3390\/cancers14184515","volume":"14","author":"SI Soliman","year":"2022","unstructured":"Soliman SI, Faraji F, Pang J, Mell LK, Califano JA, Orosco RK. Adjuvant radiotherapy in surgically treated HPV-positive oropharyngeal carcinoma with adverse pathological features. Cancers (Basel). 2022;14:4515. https:\/\/doi.org\/10.3390\/cancers14184515.","journal-title":"Cancers (Basel)"},{"key":"4385_CR64","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/hed.23136","volume":"34","author":"DJ Adelstein","year":"2012","unstructured":"Adelstein DJ, Ridge JA, Brizel DM, Holsinger FC, Haughey BH, O\u2019Sullivan B, et al. Transoral resection of pharyngeal cancer: summary of a National Cancer Institute Head and Neck Cancer Steering Committee Clinical Trials Planning Meeting, November 6\u20137, 2011, Arlington, Virginia. Head Neck. 2012;34:1681\u2013703. https:\/\/doi.org\/10.1002\/hed.23136.","journal-title":"Head Neck"},{"key":"4385_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/lary.20552","author":"JT Rich","year":"2009","unstructured":"Rich JT, Milov S, Lewis JS, Thorstad WL, Adkins DR, Haughey BH. Transoral laser microsurgery (TLM) \u00b1 adjuvant therapy for advanced stage oropharyngeal cancer: outcomes and prognostic factors. Laryngoscope. 2009. https:\/\/doi.org\/10.1002\/lary.20552.","journal-title":"Laryngoscope"},{"key":"4385_CR66","doi-asserted-by":"publisher","first-page":"S99","DOI":"10.14639\/0392-100X-suppl.1-45-2025-N1078","volume":"45","author":"F Mattioli","year":"2025","unstructured":"Mattioli F, Succo G, Piazza F, Gillone C, Ferulli G, Alberti C, et al. The impact of resection margins in hypopharyngeal surgery: a systematic review and meta-analysis. Acta Otorhinolaryngol Ital. 2025;45:S99-108. https:\/\/doi.org\/10.14639\/0392-100X-suppl.1-45-2025-N1078.","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"4385_CR67","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1186\/s12885-020-06793-6","volume":"20","author":"D Wang","year":"2020","unstructured":"Wang D, Yu S, Zhai L, Xu J, Li B. Patterns of regional lymph node failure of locally advanced hypopharyngeal squamous cell carcinoma after first-line treatment with surgery and\/or intensity-modulated radiotherapy. BMC Cancer. 2020;20:283. https:\/\/doi.org\/10.1186\/s12885-020-06793-6.","journal-title":"BMC Cancer"},{"key":"4385_CR68","doi-asserted-by":"publisher","unstructured":"Updates on Treatments and Management of Nasopharyngeal Carcinoma|American Society of Clinical Oncology Educational Book n.d. https:\/\/ascopubs.org\/doi\/https:\/\/doi.org\/10.1200\/EDBK-25-472460 (accessed March 30, 2026).","DOI":"10.1200\/EDBK-25-472460"},{"key":"4385_CR69","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s11864-023-01083-2","volume":"24","author":"JJ Juarez-Vignon Whaley","year":"2023","unstructured":"Juarez-Vignon Whaley JJ, Afkhami M, Sampath S, Amini A, Bell D, Villaflor VM. Early stage and locally advanced nasopharyngeal carcinoma treatment from present to future: where are we and where are we going? Curr Treat Options in Oncol. 2023;24:845\u201366. https:\/\/doi.org\/10.1007\/s11864-023-01083-2.","journal-title":"Curr Treat Options in Oncol"},{"key":"4385_CR70","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12885-024-12155-3","volume":"24","author":"A Cirillo","year":"2024","unstructured":"Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, De Vincentiis M, et al. Pembrolizumab-based first-line treatment for PD-L1-positive, recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis. BMC Cancer. 2024;24:430. https:\/\/doi.org\/10.1186\/s12885-024-12155-3.","journal-title":"BMC Cancer"},{"key":"4385_CR71","unstructured":"Stenger M. Pembrolizumab in First-Line Treatment of Head\/Neck Squamous Cell Carcinoma n.d. https:\/\/ascopost.com\/issues\/september-10-2019\/pembrolizumab-in-first-line-treatment-of-headneck-squamous-cell-carcinoma\/ (accessed March 30, 2026)."},{"key":"4385_CR72","doi-asserted-by":"publisher","first-page":"1348045","DOI":"10.3389\/fonc.2024.1348045","volume":"14","author":"CM Black","year":"2024","unstructured":"Black CM, Zheng D, Hair GM, Ai L, Wang L, Goto D, et al. Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent \/ metastatic head and neck squamous cell carcinoma. Front Oncol. 2024;14:1348045. https:\/\/doi.org\/10.3389\/fonc.2024.1348045.","journal-title":"Front Oncol"},{"key":"4385_CR73","unstructured":"The ASCO Post n.d. https:\/\/ascopost.com\/News\/60093 (accessed March 30, 2026)."},{"key":"4385_CR74","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2020.12853","author":"M Tahara","year":"2020","unstructured":"Tahara M, Doi I, Murata T, Mishina S, Takai S, Kaneko H. Re-challenge of platinum-based chemotherapy for platinum-refractory patients with recurrent or metastatic head and neck cancer: claims data analysis in Japan. JHEOR. 2020. https:\/\/doi.org\/10.36469\/jheor.2020.12853.","journal-title":"JHEOR"},{"key":"4385_CR75","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1097\/IGC.0b013e318217b30b","volume":"21","author":"JA Ledermann","year":"2011","unstructured":"Ledermann JA. Benefits of enhancing the platinum-free interval in the treatment of relapsed ovarian cancer. Int J Gynecol Cancer. 2011;21:S9-11. https:\/\/doi.org\/10.1097\/IGC.0b013e318217b30b.","journal-title":"Int J Gynecol Cancer"},{"key":"4385_CR76","doi-asserted-by":"publisher","first-page":"1161931","DOI":"10.3389\/fonc.2023.1161931","volume":"13","author":"J Sands","year":"2023","unstructured":"Sands J, Subramanian J. Treating patients with platinum-sensitive extensive-stage small-cell lung cancer in a real-world setting. Front Oncol. 2023;13:1161931. https:\/\/doi.org\/10.3389\/fonc.2023.1161931.","journal-title":"Front Oncol"},{"key":"4385_CR77","unstructured":"A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab, in patients with recurrent\/metastatic HPV16+ head and neck squamous cell cancer (R\/M HNSCC). - ASCO n.d. https:\/\/www.asco.org\/abstracts-presentations\/239189 (accessed March 30, 2026)."},{"key":"4385_CR78","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/v17050712","volume":"17","author":"F Sun","year":"2025","unstructured":"Sun F, Colevas AD. Update: immunotherapeutic strategies in HPV-associated head and neck squamous cell carcinoma. Viruses. 2025;17:712. https:\/\/doi.org\/10.3390\/v17050712.","journal-title":"Viruses"},{"key":"4385_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105038","volume":"112","author":"A Alves","year":"2021","unstructured":"Alves A, Diel L, Ramos G, Pinto A, Bernardi L, Yates 3rd J, Lamers M. Tumor microenvironment and Oral Squamous Cell Carcinoma: a crosstalk between the inflammatory state and tumor cell migration. Oral Oncol. 2021;112:105038. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105038.","journal-title":"Oral Oncol"},{"key":"4385_CR80","doi-asserted-by":"publisher","first-page":"706286","DOI":"10.3389\/fcell.2021.706286","volume":"9","author":"N Tong","year":"2021","unstructured":"Tong N, He Z, Ma Y, Wang Z, Huang Z, Cao H, et al. Tumor associated macrophages, as the dominant immune cells, are an indispensable target for immunologically cold tumor\u2014glioma therapy? Front Cell Dev Biol. 2021;9:706286. https:\/\/doi.org\/10.3389\/fcell.2021.706286.","journal-title":"Front Cell Dev Biol"},{"key":"4385_CR81","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12943-019-0983-5","volume":"18","author":"B Peltanova","year":"2019","unstructured":"Peltanova B, Raudenska M, Masarik M. Effect of tumor microenvironment on pathogenesis of the head and neck squamous cell carcinoma: a systematic review. Mol Cancer. 2019;18:63. https:\/\/doi.org\/10.1186\/s12943-019-0983-5.","journal-title":"Mol Cancer"},{"key":"4385_CR82","doi-asserted-by":"publisher","first-page":"104723","DOI":"10.1016\/j.oraloncology.2020.104723","volume":"106","author":"B Li","year":"2020","unstructured":"Li B, Ren M, Zhou X, Han Q, Cheng L. Targeting tumor-associated macrophages in head and neck squamous cell carcinoma. Oral Oncol. 2020;106:104723. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104723.","journal-title":"Oral Oncol"},{"key":"4385_CR83","doi-asserted-by":"publisher","first-page":"8203","DOI":"10.2174\/0929867328666210720143721","volume":"28","author":"S Dallavalasa","year":"2021","unstructured":"Dallavalasa S, Beeraka NM, Basavaraju CG, Tulimilli SV, Sadhu SP, Rajesh K, et al. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance, angiogenesis and metastasis\u2014current status. Curr Med Chem. 2021;28:8203\u201336. https:\/\/doi.org\/10.2174\/0929867328666210720143721.","journal-title":"Curr Med Chem"},{"key":"4385_CR84","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3892\/or.2020.7628","volume":"44","author":"E Fu","year":"2020","unstructured":"Fu E, Liu T, Yu S, Chen X, Song L, Lou H, et al. M2 macrophages reduce the radiosensitivity of head and neck cancer by releasing HB-EGF. Oncol Rep. 2020;44:698\u2013710. https:\/\/doi.org\/10.3892\/or.2020.7628.","journal-title":"Oncol Rep"},{"key":"4385_CR85","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00011-015-0874-1","volume":"65","author":"S Bashir","year":"2016","unstructured":"Bashir S, Sharma Y, Elahi A, Khan F. Macrophage polarization: the link between inflammation and related diseases. Inflamm Res. 2016;65:1\u201311. https:\/\/doi.org\/10.1007\/s00011-015-0874-1.","journal-title":"Inflamm Res"},{"key":"4385_CR86","doi-asserted-by":"publisher","first-page":"1026954","DOI":"10.3389\/fimmu.2022.1026954","volume":"13","author":"C Kerneur","year":"2022","unstructured":"Kerneur C, Cano CE, Olive D. Major pathways involved in macrophage polarization in cancer. Front Immunol. 2022;13:1026954. https:\/\/doi.org\/10.3389\/fimmu.2022.1026954.","journal-title":"Front Immunol"},{"key":"4385_CR87","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.3390\/cancers12051060","volume":"12","author":"JR Lechien","year":"2020","unstructured":"Lechien JR, Descamps G, Seminerio I, Furgiuele S, Dequanter D, Mouawad F, et al. HPV involvement in the tumor microenvironment and immune treatment in head and neck squamous cell carcinomas. Cancers. 2020;12:1060. https:\/\/doi.org\/10.3390\/cancers12051060.","journal-title":"Cancers"},{"key":"4385_CR88","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41597-023-02611-3","volume":"10","author":"Z Wang","year":"2023","unstructured":"Wang Z, Wang Q, Tao Y, Chen J, Yuan Z, Wang P. Characterization of immune microenvironment in patients with HPV-positive and negative head and neck cancer. Sci Data. 2023;10:694. https:\/\/doi.org\/10.1038\/s41597-023-02611-3.","journal-title":"Sci Data"},{"key":"4385_CR89","doi-asserted-by":"publisher","first-page":"119914","DOI":"10.1016\/j.lfs.2021.119914","volume":"284","author":"L Wang","year":"2021","unstructured":"Wang L, Lu Q, Gao W, Yu S. Recent advancement on development of drug-induced macrophage polarization in control of human diseases. Life Sci. 2021;284:119914. https:\/\/doi.org\/10.1016\/j.lfs.2021.119914.","journal-title":"Life Sci"},{"key":"4385_CR90","doi-asserted-by":"publisher","first-page":"e001341","DOI":"10.1136\/jitc-2020-001341","volume":"9","author":"C Li","year":"2021","unstructured":"Li C, Xu X, Wei S, Jiang P, Xue L, Wang J. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer. 2021;9:e001341. https:\/\/doi.org\/10.1136\/jitc-2020-001341.","journal-title":"J Immunother Cancer"},{"key":"4385_CR91","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-022-02272-x","volume":"41","author":"N Kumari","year":"2022","unstructured":"Kumari N, Choi SH. Tumor-associated macrophages in cancer: recent advancements in cancer nanoimmunotherapies. J Exp Clin Cancer Res. 2022;41:68. https:\/\/doi.org\/10.1186\/s13046-022-02272-x.","journal-title":"J Exp Clin Cancer Res"},{"key":"4385_CR92","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu VCSR, Xu H, Pan C, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41:119. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"4385_CR93","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi L, Humeau J, Buqu\u00e9 A, Zitvogel L, Kroemer G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020;17:725\u201341. https:\/\/doi.org\/10.1038\/s41571-020-0413-z.","journal-title":"Nat Rev Clin Oncol"},{"key":"4385_CR94","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/nyas.14377","volume":"1499","author":"M Lopez-Yrigoyen","year":"2021","unstructured":"Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. Ann N Y Acad Sci. 2021;1499:18\u201341. https:\/\/doi.org\/10.1111\/nyas.14377.","journal-title":"Ann N Y Acad Sci"},{"key":"4385_CR95","doi-asserted-by":"publisher","first-page":"1337129","DOI":"10.3389\/fimmu.2024.1337129","volume":"15","author":"C Lin","year":"2024","unstructured":"Lin C, Chu Y, Zheng Y, Gu S, Hu Y, He J, et al. Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma. Front Immunol. 2024;15:1337129. https:\/\/doi.org\/10.3389\/fimmu.2024.1337129.","journal-title":"Front Immunol"},{"key":"4385_CR96","doi-asserted-by":"publisher","first-page":"1213716","DOI":"10.3389\/fimmu.2023.1213716","volume":"14","author":"C Hu","year":"2023","unstructured":"Hu C, Liu M, Li Y, Zhao Y, Sharma A, Liu H, et al. Recent advances and future perspectives of CAR-T cell therapy in head and neck cancer. Front Immunol. 2023;14:1213716. https:\/\/doi.org\/10.3389\/fimmu.2023.1213716.","journal-title":"Front Immunol"},{"key":"4385_CR97","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1038\/s41409-020-0807-7","volume":"55","author":"A Jin","year":"2020","unstructured":"Jin A, Feng J, Wei G, Wu W, Yang L, Xu H, et al. CD19\/CD22 chimeric antigen receptor T-cell therapy for refractory acute B-cell lymphoblastic leukemia with FLT3-ITD mutations. Bone Marrow Transplant. 2020;55:717\u201321. https:\/\/doi.org\/10.1038\/s41409-020-0807-7.","journal-title":"Bone Marrow Transplant"},{"key":"4385_CR98","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1200\/JCO.22.00332","volume":"41","author":"RI Haddad","year":"2023","unstructured":"Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, et al. Nivolumab plus Ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651. JCO. 2023;41:2166\u201380. https:\/\/doi.org\/10.1200\/JCO.22.00332.","journal-title":"JCO"},{"key":"4385_CR99","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2020.02.015","volume":"52","author":"M Guilliams","year":"2020","unstructured":"Guilliams M, Thierry GR, Bonnardel J, Bajenoff M. Establishment and maintenance of the macrophage niche. Immunity. 2020;52:434\u201351. https:\/\/doi.org\/10.1016\/j.immuni.2020.02.015.","journal-title":"Immunity"},{"key":"4385_CR100","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/eLife.36688","volume":"7","author":"MA Morrissey","year":"2018","unstructured":"Morrissey MA, Williamson AP, Steinbach AM, Roberts EW, Kern N, Headley MB, et al. Chimeric antigen receptors that trigger phagocytosis. eLife. 2018;7:e36688. https:\/\/doi.org\/10.7554\/eLife.36688.","journal-title":"eLife"},{"key":"4385_CR101","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41416-019-0578-3","volume":"121","author":"W Zhang","year":"2019","unstructured":"Zhang W, Liu L, Su H, Liu Q, Shen J, Dai H, et al. Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. Br J Cancer. 2019;121:837\u201345. https:\/\/doi.org\/10.1038\/s41416-019-0578-3.","journal-title":"Br J Cancer"},{"key":"4385_CR102","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","journal-title":"Nat Med"},{"key":"4385_CR103","doi-asserted-by":"publisher","first-page":"103873","DOI":"10.1016\/j.ebiom.2022.103873","volume":"76","author":"S Wang","year":"2022","unstructured":"Wang S, Yang Y, Ma P, Zha Y, Zhang J, Lei A, et al. CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine. 2022;76:103873. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103873.","journal-title":"EBioMedicine"},{"key":"4385_CR104","doi-asserted-by":"publisher","first-page":"2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex\u2010mediated in vivo programming to chimeric antigen receptor\u2010M1 macrophages for cancer therapy. Adv Mater. 2021;33:2103258. https:\/\/doi.org\/10.1002\/adma.202103258.","journal-title":"Adv Mater"},{"key":"4385_CR105","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","volume":"13","author":"A Elmusrati","year":"2021","unstructured":"Elmusrati A, Wang J, Wang C-Y. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13:24. https:\/\/doi.org\/10.1038\/s41368-021-00131-7.","journal-title":"Int J Oral Sci"},{"key":"4385_CR106","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41577-024-00994-x","volume":"24","author":"TS Sumida","year":"2024","unstructured":"Sumida TS, Cheru NT, Hafler DA. The regulation and differentiation of regulatory T cells and their dysfunction in autoimmune diseases. Nat Rev Immunol. 2024;24:503\u201317. https:\/\/doi.org\/10.1038\/s41577-024-00994-x.","journal-title":"Nat Rev Immunol"},{"key":"4385_CR107","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1172\/JCI200423395","volume":"114","author":"Z Feh\u00e9rvari","year":"2004","unstructured":"Feh\u00e9rvari Z, Sakaguchi S. CD4+ Tregs and immune control. J Clin Invest. 2004;114:1209\u201317. https:\/\/doi.org\/10.1172\/JCI200423395.","journal-title":"J Clin Invest"},{"key":"4385_CR108","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/cancers16061113","volume":"16","author":"F Batrash","year":"2024","unstructured":"Batrash F, Shaik A, Rauf R, Kutmah M, Zhang J. Paracrine regulation and immune system pathways in the inflammatory tumor microenvironment of lung cancer: insights into oncogenesis and immunotherapeutic strategies. Cancers. 2024;16:1113. https:\/\/doi.org\/10.3390\/cancers16061113.","journal-title":"Cancers"},{"key":"4385_CR109","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/cr.2016.151","volume":"27","author":"A Tanaka","year":"2017","unstructured":"Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Cell Res. 2017;27:109\u201318. https:\/\/doi.org\/10.1038\/cr.2016.151.","journal-title":"Cell Res"},{"key":"4385_CR110","doi-asserted-by":"publisher","first-page":"e2023739118","DOI":"10.1073\/pnas.2023739118","volume":"118","author":"M Tekguc","year":"2021","unstructured":"Tekguc M, Wing JB, Osaki M, Long J, Sakaguchi S. Treg-expressed CTLA-4 depletes CD80\/CD86 by trogocytosis, releasing free PD-L1 on antigen-presenting cells. Proc Natl Acad Sci USA. 2021;118:e2023739118. https:\/\/doi.org\/10.1073\/pnas.2023739118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4385_CR111","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.mce.2013.06.003","volume":"382","author":"X Jiang","year":"2014","unstructured":"Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382:673\u201382. https:\/\/doi.org\/10.1016\/j.mce.2013.06.003.","journal-title":"Mol Cell Endocrinol"},{"key":"4385_CR112","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41419-025-07544-w","volume":"16","author":"Y Pan","year":"2025","unstructured":"Pan Y, Zhou H, Sun Z, Zhu Y, Zhang Z, Han J, et al. Regulatory T cells in solid tumor immunotherapy: effect, mechanism and clinical application. Cell Death Dis. 2025;16:277. https:\/\/doi.org\/10.1038\/s41419-025-07544-w.","journal-title":"Cell Death Dis"},{"key":"4385_CR113","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520:373\u20137. https:\/\/doi.org\/10.1038\/nature14292.","journal-title":"Nature"},{"key":"4385_CR114","doi-asserted-by":"publisher","first-page":"003685042412660","DOI":"10.1177\/00368504241266087","volume":"107","author":"F Teveto\u011flu","year":"2024","unstructured":"Teveto\u011flu F, \u00c7omuno\u011flu N, Yener HM. The impact of the tumor immune microenvironment and tumor-infiltrating lymphocyte subgroups on laryngeal cancer prognosis. Sci Prog. 2024;107:00368504241266087. https:\/\/doi.org\/10.1177\/00368504241266087.","journal-title":"Sci Prog"},{"key":"4385_CR115","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s40001-022-00835-4","volume":"27","author":"C Liu","year":"2022","unstructured":"Liu C, Wang M, Zhang H, Li C, Zhang T, Liu H, et al. Tumor microenvironment and immunotherapy of oral cancer. Eur J Med Res. 2022;27:198. https:\/\/doi.org\/10.1186\/s40001-022-00835-4.","journal-title":"Eur J Med Res"},{"key":"4385_CR116","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1038\/bjc.2013.645","volume":"109","author":"H-B Jie","year":"2013","unstructured":"Jie H-B, Gildener-Leapman N, Li J, Srivastava RM, Gibson SP, Whiteside TL, et al. Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients. Br J Cancer. 2013;109:2629\u201335. https:\/\/doi.org\/10.1038\/bjc.2013.645.","journal-title":"Br J Cancer"},{"key":"4385_CR117","doi-asserted-by":"publisher","first-page":"15179","DOI":"10.1038\/srep15179","volume":"5","author":"B Shang","year":"2015","unstructured":"Shang B, Liu Y, Jiang S, Liu Y. Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis. Sci Rep. 2015;5:15179. https:\/\/doi.org\/10.1038\/srep15179.","journal-title":"Sci Rep"},{"key":"4385_CR118","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/cancers13040781","volume":"13","author":"D Borsetto","year":"2021","unstructured":"Borsetto D, Tomasoni M, Payne K, Polesel J, Deganello A, Bossi P, et al. Prognostic significance of CD4+ and CD8+ tumor-infiltrating lymphocytes in head and neck squamous cell carcinoma: a meta-analysis. Cancers. 2021;13:781. https:\/\/doi.org\/10.3390\/cancers13040781.","journal-title":"Cancers"},{"key":"4385_CR119","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.3390\/cancers11111627","volume":"11","author":"A Thyagarajan","year":"2019","unstructured":"Thyagarajan A, Alshehri MSA, Miller KLR, Sherwin CM, Travers JB, Sahu RP. Myeloid-derived suppressor cells and pancreatic cancer: implications in novel therapeutic approaches. Cancers. 2019;11:1627. https:\/\/doi.org\/10.3390\/cancers11111627.","journal-title":"Cancers"},{"key":"4385_CR120","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.3389\/fimmu.2019.01099","volume":"10","author":"G Pawelec","year":"2019","unstructured":"Pawelec G, Verschoor CP, Ostrand-Rosenberg S. Myeloid-derived suppressor cells: not only in tumor immunity. Front Immunol. 2019;10:1099. https:\/\/doi.org\/10.3389\/fimmu.2019.01099.","journal-title":"Front Immunol"},{"key":"4385_CR121","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.coi.2018.03.007","volume":"51","author":"S Ostrand-Rosenberg","year":"2018","unstructured":"Ostrand-Rosenberg S. Myeloid derived-suppressor cells: their role in cancer and obesity. Curr Opin Immunol. 2018;51:68\u201375. https:\/\/doi.org\/10.1016\/j.coi.2018.03.007.","journal-title":"Curr Opin Immunol"},{"key":"4385_CR122","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3390\/cells13050413","volume":"13","author":"C-W Wang","year":"2024","unstructured":"Wang C-W, Biswas PK, Islam A, Chen M-K, Chueh PJ. The use of immune regulation in treating head and neck squamous cell carcinoma (HNSCC). Cells. 2024;13:413. https:\/\/doi.org\/10.3390\/cells13050413.","journal-title":"Cells"},{"key":"4385_CR123","doi-asserted-by":"publisher","first-page":"e0229089","DOI":"10.1371\/journal.pone.0229089","volume":"15","author":"X Pang","year":"2020","unstructured":"Pang X, Fan H, Tang Y, Wang S, Cao M, Wang H, et al. Myeloid derived suppressor cells contribute to the malignant progression of oral squamous cell carcinoma. PLoS ONE. 2020;15:e0229089. https:\/\/doi.org\/10.1371\/journal.pone.0229089.","journal-title":"PLoS ONE"},{"key":"4385_CR124","doi-asserted-by":"publisher","first-page":"110243","DOI":"10.1016\/j.intimp.2023.110243","volume":"119","author":"J Liu","year":"2023","unstructured":"Liu J, Lin W-P, Su W, Wu Z-Z, Yang Q-C, Wang S, et al. Sunitinib attenuates reactive MDSCs enhancing anti-tumor immunity in HNSCC. Int Immunopharmacol. 2023;119:110243. https:\/\/doi.org\/10.1016\/j.intimp.2023.110243.","journal-title":"Int Immunopharmacol"},{"key":"4385_CR125","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40364-025-00783-1","volume":"13","author":"S Saeidpour Masouleh","year":"2025","unstructured":"Saeidpour Masouleh S, Nasiri K, Ostovar Ravari A, Saligheh Rad M, Kiani K, Sharifi Sultani A, et al. Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma. Biomark Res. 2025;13:69. https:\/\/doi.org\/10.1186\/s40364-025-00783-1.","journal-title":"Biomark Res"},{"key":"4385_CR126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-025-01744-9","volume":"18","author":"M-C Vo","year":"2025","unstructured":"Vo M-C, Tran V-D-H, Nguyen V-T, Ruzimurodov N, Trung DT, Kim SK, et al. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? J Hematol Oncol. 2025;18:91. https:\/\/doi.org\/10.1186\/s13045-025-01744-9.","journal-title":"J Hematol Oncol"},{"key":"4385_CR127","doi-asserted-by":"publisher","first-page":"3972","DOI":"10.3390\/cancers14163972","volume":"14","author":"C Peterson","year":"2022","unstructured":"Peterson C, Denlinger N, Yang Y. Recent advances and challenges in cancer immunotherapy. Cancers. 2022;14:3972. https:\/\/doi.org\/10.3390\/cancers14163972.","journal-title":"Cancers"},{"key":"4385_CR128","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.immuni.2019.11.014","volume":"52","author":"AR Cillo","year":"2020","unstructured":"Cillo AR, K\u00fcrten CHL, Tabib T, Qi Z, Onkar S, Wang T, et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity. 2020;52:183-199.e9. https:\/\/doi.org\/10.1016\/j.immuni.2019.11.014.","journal-title":"Immunity"},{"key":"4385_CR129","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1200\/JCO.2015.61.1509","volume":"33","author":"RL Ferris","year":"2015","unstructured":"Ferris RL. Immunology and immunotherapy of head and neck cancer. JCO. 2015;33:3293\u2013304. https:\/\/doi.org\/10.1200\/JCO.2015.61.1509.","journal-title":"JCO"},{"key":"4385_CR130","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(18)31999-8","volume":"393","author":"EEW Cohen","year":"2019","unstructured":"Cohen EEW, Souli\u00e8res D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. The Lancet. 2019;393:156\u201367. https:\/\/doi.org\/10.1016\/S0140-6736(18)31999-8.","journal-title":"The Lancet"},{"key":"4385_CR131","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"key":"4385_CR132","doi-asserted-by":"publisher","first-page":"e218065","DOI":"10.1001\/jamanetworkopen.2021.8065","volume":"4","author":"R Pei","year":"2021","unstructured":"Pei R, Shi Y, Lv S, Dai T, Zhang F, Liu S, et al. Nivolumab vs Pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: A network meta-analysis and cost-effectiveness analysis. JAMA Netw Open. 2021;4:e218065. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8065.","journal-title":"JAMA Netw Open"},{"key":"4385_CR133","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1200\/JCO.21.02508","volume":"41","author":"KJ Harrington","year":"2023","unstructured":"Harrington KJ, Burtness B, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: Updated results of the phase III KEYNOTE-048 study. J Clin Oncol. 2023;41:790\u2013802. https:\/\/doi.org\/10.1200\/JCO.21.02508.","journal-title":"J Clin Oncol"},{"key":"4385_CR134","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1200\/JCO.22.01015","volume":"41","author":"VM Patil","year":"2023","unstructured":"Patil VM, Noronha V, Menon N, Rai R, Bhattacharjee A, Singh A, et al. Low-dose immunotherapy in head and neck cancer: A randomized study. J Clin Oncol. 2023;41:222\u201332. https:\/\/doi.org\/10.1200\/JCO.22.01015.","journal-title":"J Clin Oncol"},{"key":"4385_CR135","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019;394:1915\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(19)32591-7.","journal-title":"Lancet"},{"key":"4385_CR136","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115395","volume":"221","author":"M Tahara","year":"2025","unstructured":"Tahara M, Greil R, Rischin D, Harrington KJ, Burtness B, de Castro G, Psyrri A, Bra\u00f1a I, Neupane P, Bratland \u00c5, Fuereder T. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study. Eur J Cancer. 2025;221: 115395.","journal-title":"Eur J Cancer."},{"key":"4385_CR137","doi-asserted-by":"publisher","first-page":"941750","DOI":"10.3389\/fcell.2022.941750","volume":"10","author":"C Yu","year":"2022","unstructured":"Yu C, Li Q, Zhang Y, Wen Z-F, Dong H, Mou Y. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma. Front Cell Dev Biol. 2022;10:941750. https:\/\/doi.org\/10.3389\/fcell.2022.941750.","journal-title":"Front Cell Dev Biol"},{"key":"4385_CR138","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1097\/MOO.0000000000000448","volume":"26","author":"S Alfieri","year":"2018","unstructured":"Alfieri S, Cavalieri S, Licitra L. Immunotherapy for recurrent\/metastatic head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2018;26:152\u20136. https:\/\/doi.org\/10.1097\/MOO.0000000000000448.","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"key":"4385_CR139","doi-asserted-by":"publisher","first-page":"5075","DOI":"10.1007\/s11030-024-10917-6","volume":"29","author":"J Fu","year":"2025","unstructured":"Fu J, Mao L, Jiao Y, Mei D, Chen Y. Elucidating CTLA-4\u2019s role in tumor immunity: a comprehensive overview of targeted antibody therapies and clinical developments. Mol Divers. 2025;29:5075\u201384. https:\/\/doi.org\/10.1007\/s11030-024-10917-6.","journal-title":"Mol Divers"},{"key":"4385_CR140","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40290-019-00288-x","volume":"33","author":"K Devaraja","year":"2019","unstructured":"Devaraja K. Current prospects of molecular therapeutics in head and neck squamous cell carcinoma. Pharm Med. 2019;33:269\u201389. https:\/\/doi.org\/10.1007\/s40290-019-00288-x.","journal-title":"Pharm Med"},{"key":"4385_CR141","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ymthe.2023.02.023","volume":"31","author":"S Wang","year":"2023","unstructured":"Wang S, Wu Z-Z, Zhu S-W, Wan S-C, Zhang M-J, Zhang B-X, et al. CTLA-4 blockade induces tumor pyroptosis via CD8+ T cells in head and neck squamous cell carcinoma. Mol Ther. 2023;31:2154\u201368. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.023.","journal-title":"Mol Ther"},{"key":"4385_CR142","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.stem.2021.04.011","volume":"28","author":"C Wang","year":"2021","unstructured":"Wang C, Li Y, Jia L, Kim Jkoo, Li J, Deng P, et al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. 2021;28:1597-1613.e7. https:\/\/doi.org\/10.1016\/j.stem.2021.04.011.","journal-title":"Cell Stem Cell"},{"key":"4385_CR143","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-15-2665","volume":"22","author":"Y Lee","year":"2016","unstructured":"Lee Y, Shin JH, Longmire M, Wang H, Kohrt HE, Chang HY, et al. CD44+ cells in head and neck squamous cell carcinoma suppress T-Cell\u2013mediated immunity by selective constitutive and inducible expression of PD-L1. Clin Cancer Res. 2016;22:3571\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2665.","journal-title":"Clin Cancer Res"},{"key":"4385_CR144","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0043-1772459","volume":"10","author":"L Kavitha","year":"2023","unstructured":"Kavitha L, Vijayashree Priyadharsini J, Kattula D, Rao UKM, Balaji Srikanth R, Kuzhalmozhi M, et al. Expression of CD44 in head and neck squamous cell carcinoma\u2014an in-silico study. Glob Med Genet. 2023;10:221\u20138. https:\/\/doi.org\/10.1055\/s-0043-1772459.","journal-title":"Glob Med Genet"},{"key":"4385_CR145","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol Mech Dis. 2021;16:223\u201349. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741.","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"4385_CR146","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S1470-2045(24)00100-1","volume":"25","author":"J-P Machiels","year":"2024","unstructured":"Machiels J-P, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, et al. Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2024;25:572\u201387. https:\/\/doi.org\/10.1016\/S1470-2045(24)00100-1.","journal-title":"Lancet Oncol"},{"key":"4385_CR147","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","volume":"34","author":"A Psyrri","year":"2023","unstructured":"Psyrri A, Fayette J, Harrington K, Gillison M, Ahn M-J, Takahashi S, et al. Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study. Ann Oncol. 2023;34:262\u201374. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.008.","journal-title":"Ann Oncol"},{"key":"4385_CR148","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41568-021-00357-x","volume":"21","author":"S Zhao","year":"2021","unstructured":"Zhao S, Allis CD, Wang GG. The language of chromatin modification in human cancers. Nat Rev Cancer. 2021;21:413\u201330. https:\/\/doi.org\/10.1038\/s41568-021-00357-x.","journal-title":"Nat Rev Cancer"},{"key":"4385_CR149","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3322\/caac.21765","volume":"73","author":"V Davalos","year":"2023","unstructured":"Davalos V, Esteller M. Cancer epigenetics in clinical practice. CA Cancer J Clin. 2023;73:376\u2013424. https:\/\/doi.org\/10.3322\/caac.21765.","journal-title":"CA Cancer J Clin"},{"key":"4385_CR150","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.mrrev.2016.09.006","volume":"772","author":"J Durzynska","year":"2017","unstructured":"Durzynska J, Lesniewicz K, Poreba E. Human papillomaviruses in epigenetic regulations. Mutat Res Rev Mutat Res. 2017;772:36\u201350. https:\/\/doi.org\/10.1016\/j.mrrev.2016.09.006.","journal-title":"Mutat Res Rev Mutat Res"},{"key":"4385_CR151","doi-asserted-by":"publisher","first-page":"146","DOI":"10.14348\/molcells.2021.0001","volume":"44","author":"MJ Kim","year":"2021","unstructured":"Kim MJ, Lee HJ, Choi MY, Kang SS, Kim YS, Shin JK, et al. UHRF1 induces methylation of the TXNIP promoter and down-regulates gene expression in cervical cancer. Mol Cells. 2021;44:146\u201359.","journal-title":"Mol Cells"},{"key":"4385_CR152","doi-asserted-by":"publisher","first-page":"507","DOI":"10.7150\/ijbs.67770","volume":"18","author":"C Hu","year":"2022","unstructured":"Hu C, Liu T, Han C, Xuan Y, Jiang D, Sun Y, et al. HPV E6\/E7 promotes aerobic glycolysis in cervical cancer by regulating IGF2BP2 to stabilize m6 A-MYC expression. Int J Biol Sci. 2022;18:507\u201321. https:\/\/doi.org\/10.7150\/ijbs.67770.","journal-title":"Int J Biol Sci"},{"key":"4385_CR153","doi-asserted-by":"publisher","first-page":"14593","DOI":"10.3390\/ijms241914593","volume":"24","author":"I Zygouras","year":"2023","unstructured":"Zygouras I, Leventakou D, Pouliakis A, Panagiotou S, Tsakogiannis D, Konstantopoulos G, et al. Human Papillomavirus 16 DNA methylation patterns and investigation of integration status in Head and Neck Cancer cases. Int J Mol Sci. 2023;24:14593. https:\/\/doi.org\/10.3390\/ijms241914593.","journal-title":"Int J Mol Sci"},{"key":"4385_CR154","doi-asserted-by":"publisher","first-page":"e4941","DOI":"10.1371\/journal.pone.0004941","volume":"4","author":"KL Richards","year":"2009","unstructured":"Richards KL, Zhang B, Baggerly KA, Colella S, Lang JC, Schuller DE, et al. Genome-wide hypomethylation in Head and Neck Cancer is more pronounced in HPV-negative tumors and is associated with genomic instability. PLoS One. 2009;4:e4941. https:\/\/doi.org\/10.1371\/journal.pone.0004941.","journal-title":"PLoS One"},{"key":"4385_CR155","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nature14129","volume":"517","author":"The Cancer Genome Atlas Network","year":"2015","unstructured":"The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517:576\u201382. https:\/\/doi.org\/10.1038\/nature14129.","journal-title":"Nature"},{"key":"4385_CR156","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/ijc.22889","volume":"121","author":"IM Smith","year":"2007","unstructured":"Smith IM, Mydlarz WK, Mithani SK, Califano JA. DNA global hypomethylation in squamous cell head and neck cancer associated with smoking, alcohol consumption and stage. Int J Cancer. 2007;121:1724\u20138. https:\/\/doi.org\/10.1002\/ijc.22889.","journal-title":"Int J Cancer"},{"key":"4385_CR157","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1158\/1078-0432.CCR-11-0044","volume":"17","author":"GM Poage","year":"2011","unstructured":"Poage GM, Houseman EA, Christensen BC, Butler RA, Avissar-Whiting M, McClean MD, et al. Global hypomethylation identifies loci targeted for hypermethylation in Head and Neck Cancer. Clin Cancer Res. 2011;17:3579\u201389. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0044.","journal-title":"Clin Cancer Res"},{"key":"4385_CR158","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/00220345241297122","volume":"104","author":"Y Li","year":"2025","unstructured":"Li Y, Lu C. Targeting epigenetic dysregulations in Head and Neck Squamous Cell Carcinoma. J Dent Res. 2025;104:225\u201334. https:\/\/doi.org\/10.1177\/00220345241297122.","journal-title":"J Dent Res"},{"key":"4385_CR159","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/s43018-021-00249-x","volume":"2","author":"MB Pappalardi","year":"2021","unstructured":"Pappalardi MB, Keenan K, Cockerill M, Kellner WA, Stowell A, Sherk C, et al. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nat Cancer. 2021;2:1002\u201317.","journal-title":"Nat Cancer"},{"key":"4385_CR160","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-024-01993-1","volume":"23","author":"Y Liu","year":"2024","unstructured":"Liu Y, Sun Y, Yang J, Wu D, Yu S, Liu J, et al. DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma. Mol Cancer. 2024;23:104. https:\/\/doi.org\/10.1186\/s12943-024-01993-1.","journal-title":"Mol Cancer"},{"key":"4385_CR161","doi-asserted-by":"publisher","first-page":"329","DOI":"10.21037\/atm.2020.02.145","volume":"8","author":"R Huang","year":"2020","unstructured":"Huang R, Wang Y, Ge H, Wang D, Wang Y, Zhang W, et al. Restoration of TET2 deficiency inhibits tumor growth in head neck squamous cell carcinoma. Ann Transl Med. 2020;8:329\u2013329. https:\/\/doi.org\/10.21037\/atm.2020.02.145.","journal-title":"Ann Transl Med"},{"key":"4385_CR162","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s11033-024-09714-z","volume":"51","author":"JK Shekhawat","year":"2024","unstructured":"Shekhawat JK, Sharma J, Choudhury B, Purohit P, Sharma P, Banerjee M. TET3 downregulation and low 5-hydroxymethylcytosine are epigenetic signatures of head and neck carcinoma. Mol Biol Rep. 2024;51:877. https:\/\/doi.org\/10.1007\/s11033-024-09714-z.","journal-title":"Mol Biol Rep"},{"key":"4385_CR163","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1016\/j.molcel.2022.09.007","volume":"82","author":"Y Li","year":"2022","unstructured":"Li Y, Goldberg EM, Chen X, Xu X, McGuire JT, Leuzzi G, et al. Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Mol Cell. 2022;82:3901-3918.e7. https:\/\/doi.org\/10.1016\/j.molcel.2022.09.007.","journal-title":"Mol Cell"},{"key":"4385_CR164","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/s10565-023-09818-5","volume":"39","author":"P Ahuja","year":"2023","unstructured":"Ahuja P, Yadav R, Goyal S, Yadav C, Ranga S, Kadian L. Targeting epigenetic deregulations for the management of esophageal carcinoma: recent advances and emerging approaches. Cell Biol Toxicol. 2023;39:2437\u201365. https:\/\/doi.org\/10.1007\/s10565-023-09818-5.","journal-title":"Cell Biol Toxicol"},{"key":"4385_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-031-75980-2_1","volume-title":"Neuroepigenetics Mechanisms in Health and Disease","author":"JR Davie","year":"2025","unstructured":"Davie JR, Sattarifard H, Sudhakar SRN, Roberts C-T, Beacon TH, Muker I, et al. Basic Epigenetic Mechanisms. In: van Zundert B, Montecino M, editors., et al., Neuroepigenetics Mechanisms in Health and Disease, vol. 108. Cham: Springer Nature Switzerland; 2025. p. 1\u201349."},{"key":"4385_CR166","doi-asserted-by":"publisher","first-page":"e58672","DOI":"10.1371\/journal.pone.0058672","volume":"8","author":"FS Giudice","year":"2013","unstructured":"Giudice FS, Pinto DS, N\u00f6r JE, Squarize CH, Castilho RM. Inhibition of histone deacetylase impacts cancer stem cells and induces epithelial-mesenchyme transition of head and neck cancer. PLoS One. 2013;8:e58672. https:\/\/doi.org\/10.1371\/journal.pone.0058672.","journal-title":"PLoS One"},{"key":"4385_CR167","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s13148-024-01785-w","volume":"16","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Zhang Y, Hu Y, Zhang X, Tan J, Yao S, et al. Advances in the study of posttranslational modifications of histones in head and neck squamous cell carcinoma. Clin Epigenet. 2024;16:165. https:\/\/doi.org\/10.1186\/s13148-024-01785-w.","journal-title":"Clin Epigenet"},{"key":"4385_CR168","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2019.4707","author":"F Chen","year":"2019","unstructured":"Chen F, Qi S, Zhang X, Wu J, Yang X, Wang R. lncRNA PLAC2 activated by H3K27 acetylation promotes cell proliferation and invasion via the activation of Wnt\/\u03b2-catenin pathway in oral squamous cell carcinoma. Int J Oncol. 2019. https:\/\/doi.org\/10.3892\/ijo.2019.4707.","journal-title":"Int J Oncol"},{"key":"4385_CR169","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-019-1123-y","volume":"19","author":"H Ma","year":"2020","unstructured":"Ma H, Chang H, Yang W, Lu Y, Hu J, Jin S. A novel IFN\u03b1-induced long noncoding RNA negatively regulates immunosuppression by interrupting H3K27 acetylation in head and neck squamous cell carcinoma. Mol Cancer. 2020;19:4. https:\/\/doi.org\/10.1186\/s12943-019-1123-y.","journal-title":"Mol Cancer"},{"key":"4385_CR170","doi-asserted-by":"publisher","first-page":"216869","DOI":"10.1016\/j.canlet.2024.216869","volume":"590","author":"Y Lu","year":"2024","unstructured":"Lu Y, Wang Y, Zhang L, Ma Z, Yu K, Shu Y, et al. KAT7 enhances the proliferation and metastasis of head and neck squamous carcinoma by promoting the acetylation level of LDHA. Cancer Lett. 2024;590:216869. https:\/\/doi.org\/10.1016\/j.canlet.2024.216869.","journal-title":"Cancer Lett"},{"key":"4385_CR171","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/ijms19061706","volume":"19","author":"NSL Yeo-Teh","year":"2018","unstructured":"Yeo-Teh NSL, Ito Y, Jha S. High-risk human papillomaviral oncogenes E6 and E7 target key cellular pathways to achieve oncogenesis. IJMS. 2018;19:1706. https:\/\/doi.org\/10.3390\/ijms19061706.","journal-title":"IJMS"},{"key":"4385_CR172","doi-asserted-by":"publisher","first-page":"e112880","DOI":"10.1371\/journal.pone.0112880","volume":"9","author":"CT Viet","year":"2014","unstructured":"Viet CT, Dang D, Achdjian S, Ye Y, Katz SG, Schmidt BL. Decitabine rescues Cisplatin resistance in head and neck squamous cell carcinoma. PLoS One. 2014;9:e112880. https:\/\/doi.org\/10.1371\/journal.pone.0112880.","journal-title":"PLoS One"},{"key":"4385_CR173","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.3390\/cancers13205241","volume":"13","author":"K Burkitt","year":"2021","unstructured":"Burkitt K, Saloura V. Epigenetic modifiers as novel therapeutic targets and a systematic review of clinical studies investigating epigenetic inhibitors in head and neck cancer. Cancers Basel. 2021;13:5241. https:\/\/doi.org\/10.3390\/cancers13205241.","journal-title":"Cancers Basel"},{"key":"4385_CR174","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10637-007-9075-2","volume":"26","author":"GR Blumenschein","year":"2008","unstructured":"Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, et al. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza\u2122, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and\/or metastatic head and neck cancer. Invest New Drugs. 2008;26:81\u20137. https:\/\/doi.org\/10.1007\/s10637-007-9075-2.","journal-title":"Invest New Drugs"},{"key":"4385_CR175","doi-asserted-by":"publisher","first-page":"19","DOI":"10.7150\/jca.16655","volume":"8","author":"A Grabarska","year":"2017","unstructured":"Grabarska A, \u0141uszczki JJ, Nowosadzka E, Gumbarewicz E, Jeleniewicz W, Dmoszy\u0144ska-Graniczka M, et al. Histone deacetylase inhibitor SAHA as potential targeted therapy agent for larynx cancer cells. J Cancer. 2017;8:19\u201328. https:\/\/doi.org\/10.7150\/jca.16655.","journal-title":"J Cancer"},{"key":"4385_CR176","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1186\/s12885-016-2888-7","volume":"16","author":"C-H Pan","year":"2016","unstructured":"Pan C-H, Chang Y-F, Lee M-S, Wen B-C, Ko J-C, Liang S-K, et al. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells. BMC Cancer. 2016;16:857. https:\/\/doi.org\/10.1186\/s12885-016-2888-7.","journal-title":"BMC Cancer"},{"key":"4385_CR177","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1007\/s10637-018-0696-4","volume":"37","author":"TN Teknos","year":"2019","unstructured":"Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, et al. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Invest New Drugs. 2019;37:702\u201310. https:\/\/doi.org\/10.1007\/s10637-018-0696-4.","journal-title":"Invest New Drugs"},{"key":"4385_CR178","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41416-019-0394-9","volume":"120","author":"S Citro","year":"2019","unstructured":"Citro S, Bellini A, Miccolo C, Ghiani L, Carey TE, Chiocca S. Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for \u0394Np63\u03b1. Br J Cancer. 2019;120:658\u201367. https:\/\/doi.org\/10.1038\/s41416-019-0394-9.","journal-title":"Br J Cancer"},{"key":"4385_CR179","doi-asserted-by":"publisher","first-page":"e30815","DOI":"10.1371\/journal.pone.0030815","volume":"7","author":"L Shen","year":"2012","unstructured":"Shen L, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone deacetylase inhibitor Entinostat suppresses regulatory T Cells and enhances immunotherapies in renal and prostate cancer models. PLoS ONE. 2012;7:e30815. https:\/\/doi.org\/10.1371\/journal.pone.0030815.","journal-title":"PLoS ONE"},{"key":"4385_CR180","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1158\/1078-0432.CCR-19-2214","volume":"26","author":"CP Rodriguez","year":"2020","unstructured":"Rodriguez CP, Wu Q (Vicky), Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, et al. A Phase II trial of Pembrolizumab and Vorinostat in recurrent metastatic head and neck squamous cell carcinomas and salivary gland cancer. Clin Cancer Res. 2020;26:837\u201345. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2214.","journal-title":"Clin Cancer Res"},{"key":"4385_CR181","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.oraloncology.2012.05.024","volume":"48","author":"M Haigentz","year":"2012","unstructured":"Haigentz M, Kim M, Sarta C, Lin J, Keresztes RS, Culliney B, et al. Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent\/metastatic head and neck cancer. Oral Oncol. 2012;48:1281\u20138. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.05.024.","journal-title":"Oral Oncol"},{"key":"4385_CR182","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s00280-008-0747-1","volume":"63","author":"RB Erlich","year":"2009","unstructured":"Erlich RB, Rickwood D, Coman WB, Saunders NA, Guminski A. Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas. Cancer Chemother Pharmacol. 2009;63:381\u20139. https:\/\/doi.org\/10.1007\/s00280-008-0747-1.","journal-title":"Cancer Chemother Pharmacol"},{"key":"4385_CR183","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2217\/epi-2020-0348","volume":"14","author":"S Suchanti","year":"2022","unstructured":"Suchanti S, Stephen BJ, Awasthi S, Awasthi SK, Singh G, Singh A, et al. Harnessing the role of epigenetic histone modification in targeting head and neck squamous cell carcinoma. Epigenomics. 2022;14:279\u201393. https:\/\/doi.org\/10.2217\/epi-2020-0348.","journal-title":"Epigenomics"},{"key":"4385_CR184","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9","volume":"88","author":"T Suzuki","year":"2000","unstructured":"Suzuki T, Yokozaki H, Kuniyasu H, Hayashi K, Naka K, Ono S, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer. 2000;88:992\u20137. https:\/\/doi.org\/10.1002\/1097-0215(20001215)88:6%3c992::AID-IJC24%3e3.0.CO;2-9.","journal-title":"Int J Cancer"},{"key":"4385_CR185","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.fob.2013.12.003","volume":"4","author":"LO Almeida","year":"2014","unstructured":"Almeida LO, Abrahao AC, Rosselli-Murai LK, Giudice FS, Zagni C, Leopoldino AM, et al. NF\u03baB mediates cisplatin resistance through histone modifications in head and neck squamous cell carcinoma (HNSCC). FEBS Open Bio. 2014;4:96\u2013104. https:\/\/doi.org\/10.1016\/j.fob.2013.12.003.","journal-title":"FEBS Open Bio"},{"key":"4385_CR186","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/cbr.2017.2418","volume":"33","author":"K Qian","year":"2018","unstructured":"Qian K, Sun L, Zhou G, Ge H, Meng Y, Li J, et al. Sodium Phenylbutyrate inhibits tumor growth and the epithelial\u2013mesenchymal transition of oral squamous cell carcinoma in vitro and in vivo. Cancer Biother Radiopharm. 2018;33:139\u201345. https:\/\/doi.org\/10.1089\/cbr.2017.2418.","journal-title":"Cancer Biother Radiopharm"},{"key":"4385_CR187","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.oraloncology.2011.07.031","volume":"47","author":"L-Y Bai","year":"2011","unstructured":"Bai L-Y, Chiu C-F, Pan S-L, Sargeant AM, Shieh T-M, Wang Y-C, et al. Antitumor activity of a novel histone deacetylase inhibitor (S)-HDAC42 in oral squamous cell carcinoma. Oral Oncol. 2011;47:1127\u201333. https:\/\/doi.org\/10.1016\/j.oraloncology.2011.07.031.","journal-title":"Oral Oncol"},{"key":"4385_CR188","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.molcel.2007.01.017","volume":"25","author":"S Kubicek","year":"2007","unstructured":"Kubicek S, O\u2019Sullivan RJ, August EM, Hickey ER, Zhang Q, Teodoro ML, et al. Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol Cell. 2007;25:473\u201381. https:\/\/doi.org\/10.1016\/j.molcel.2007.01.017.","journal-title":"Mol Cell"},{"key":"4385_CR189","doi-asserted-by":"publisher","first-page":"eabo8043","DOI":"10.1126\/sciadv.abo8043","volume":"8","author":"A Piunti","year":"2022","unstructured":"Piunti A, Meghani K, Yu Y, Robertson AG, Podojil JR, McLaughlin KA, et al. Immune activation is essential for the antitumor activity of EZH2 inhibition in urothelial carcinoma. Sci Adv. 2022;8:eabo8043. https:\/\/doi.org\/10.1126\/sciadv.abo8043.","journal-title":"Sci Adv"},{"issue":"1","key":"4385_CR190","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.bbrc.2015.01.068","volume":"459","author":"A Ren","year":"2015","unstructured":"Ren A, Qiu Y, Cui H, Fu G. Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma. Biochem Biophys Res Commun. 2015;459(1):10\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"4385_CR191","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/1078-0432.CCR-12-2505","volume":"19","author":"OM Gannon","year":"2013","unstructured":"Gannon OM, Merida de Long L, Endo-Munoz L, Hazar-Rethinam M, Saunders NA. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation. Clin Cancer Res. 2013;19:428\u201341. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2505.","journal-title":"Clin Cancer Res"},{"key":"4385_CR192","doi-asserted-by":"publisher","first-page":"10571","DOI":"10.1074\/jbc.M115.700021","volume":"291","author":"LYW Bourguignon","year":"2016","unstructured":"Bourguignon LYW, Wong G, Shiina M. Up-regulation of histone methyltransferase, DOT1L, by matrix hyaluronan promotes MicroRNA-10 expression leading to tumor cell invasion and chemoresistance in cancer stem cells from head and neck squamous cell carcinoma. J Biol Chem. 2016;291:10571\u201385. https:\/\/doi.org\/10.1074\/jbc.M115.700021.","journal-title":"J Biol Chem"},{"key":"4385_CR193","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13148-017-0390-y","volume":"9","author":"CD Lindsay","year":"2017","unstructured":"Lindsay CD, Kostiuk MA, Harris J, O\u2019Connell DA, Seikaly H, Biron VL. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. Clin Epigenetics. 2017;9:95. https:\/\/doi.org\/10.1186\/s13148-017-0390-y.","journal-title":"Clin Epigenetics"},{"key":"4385_CR194","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","volume":"8","author":"N Wang","year":"2023","unstructured":"Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Sig Transduct Target Ther. 2023;8:69. https:\/\/doi.org\/10.1038\/s41392-023-01341-7.","journal-title":"Sig Transduct Target Ther"},{"key":"4385_CR195","doi-asserted-by":"publisher","first-page":"73372","DOI":"10.18632\/oncotarget.19637","volume":"8","author":"SF Alsaqer","year":"2017","unstructured":"Alsaqer SF, Tashkandi MM, Kartha VK, Yang Y-T, Alkheriji Y, Salama A, et al. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017;8:73372\u201386. https:\/\/doi.org\/10.18632\/oncotarget.19637.","journal-title":"Oncotarget"},{"key":"4385_CR196","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1080\/15592294.2016.1265710","volume":"12","author":"M P\u00e9rez-Salvia","year":"2017","unstructured":"P\u00e9rez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: From structures to applications. Epigenetics. 2017;12:323\u201339. https:\/\/doi.org\/10.1080\/15592294.2016.1265710.","journal-title":"Epigenetics"},{"key":"4385_CR197","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3892\/or.2024.8733","volume":"51","author":"V Yongprayoon","year":"2024","unstructured":"Yongprayoon V, Wattanakul N, Khomate W, Apithanangsiri N, Kasitipradit T, Nantajit D, et al. Targeting BRD4: Potential therapeutic strategy for head and neck squamous cell carcinoma (Review). Oncol Rep. 2024;51:74. https:\/\/doi.org\/10.3892\/or.2024.8733.","journal-title":"Oncol Rep"},{"key":"4385_CR198","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.1016\/j.ymthe.2022.07.022","volume":"30","author":"M Zhang","year":"2022","unstructured":"Zhang M, Wang G, Ma Z, Xiong G, Wang W, Huang Z, et al. BET inhibition triggers antitumor immunity by enhancing MHC class I expression in head and neck squamous cell carcinoma. Mol Ther. 2022;30:3394\u2013413. https:\/\/doi.org\/10.1016\/j.ymthe.2022.07.022.","journal-title":"Mol Ther"},{"key":"4385_CR199","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000545","author":"W Wang","year":"2024","unstructured":"Wang W, Bi X, Feng Y, Ming X, Saina G, Kun W, et al. Efficacy and safety of immune checkpoint inhibitors on advanced cervical cancer: a systematic review and meta-analysis. J Immunother. 2024. https:\/\/doi.org\/10.1097\/CJI.0000000000000545.","journal-title":"J Immunother"},{"key":"4385_CR200","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13046-024-02996-y","volume":"43","author":"H Cai","year":"2024","unstructured":"Cai H, Liang J, Jiang Y, Wang Z, Li H, Wang W, et al. KLF7 regulates super-enhancer-driven IGF2BP2 overexpression to promote the progression of head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2024;43:69. https:\/\/doi.org\/10.1186\/s13046-024-02996-y.","journal-title":"J Exp Clin Cancer Res"},{"key":"4385_CR201","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1039\/D5RA09034B","volume":"16","author":"AE Abdallah","year":"2026","unstructured":"Abdallah AE. HDAC inhibitors as anticancer drugs: chemical diversity, clinical trials, challenges and perspectives. RSC Adv. 2026;16:3430\u201342. https:\/\/doi.org\/10.1039\/D5RA09034B.","journal-title":"RSC Adv"},{"key":"4385_CR202","doi-asserted-by":"publisher","first-page":"e181671","DOI":"10.1172\/JCI181671","volume":"135","author":"T Qin","year":"2025","unstructured":"Qin T, Mattox AK, Campbell JS, Park JC, Shin K-Y, Li S, et al. Epigenetic therapy sensitizes anti\u2013PD-1 refractory head and neck cancers to immunotherapy rechallenge. J Clin Invest. 2025;135:e181671. https:\/\/doi.org\/10.1172\/JCI181671.","journal-title":"J Clin Invest"},{"key":"4385_CR203","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v16.i8.108768","author":"S Xiao","year":"2025","unstructured":"Xiao S, Xu X-Z, Liao M, Song D-D, Tang J-F, Zhou C-F. Potential risks of histone deacetylase inhibitors in cancer therapeutics and feasible combination therapeutic strategies. World J Clin Oncol. 2025. https:\/\/doi.org\/10.5306\/wjco.v16.i8.108768.","journal-title":"World J Clin Oncol"},{"key":"4385_CR204","doi-asserted-by":"publisher","first-page":"e2250607","DOI":"10.1001\/jamanetworkopen.2022.50607","volume":"6","author":"A Lee","year":"2023","unstructured":"Lee A, Woods R, Mahfouz A, Kitpanit S, Cartano O, Mohamed N, et al. Evaluation of proton therapy reirradiation for patients with recurrent head and neck squamous cell carcinoma. JAMA Netw Open. 2023;6:e2250607. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.50607.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"4385_CR205","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101418","volume":"9","author":"K Hsieh","year":"2024","unstructured":"Hsieh K, Hotca AE, Dickstein DR, Lehrer EJ, Hsieh C, Gupta V, Sindhu KK, Liu JT, Reed SH, Chhabra A, Misiukiewicz K. Adjuvant reirradiation with proton therapy in head and neck squamous cell carcinoma. Adv Radiat Oncol. 2024;9(4): 101418.","journal-title":"Adv Radiat Oncol."},{"key":"4385_CR206","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.ijrobp.2024.01.077","volume":"118","author":"RL Bakst","year":"2024","unstructured":"Bakst RL, Hsieh K, Genden E, Sindhu K, Dickstein DR, Posner M, et al. Proton re-irradiation in the adjuvant setting for head and neck squamous cell carcinoma with high risk features. Int J Radiat Oncol Biol Phys. 2024;118:e33. https:\/\/doi.org\/10.1016\/j.ijrobp.2024.01.077.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4385_CR207","doi-asserted-by":"publisher","first-page":"106778","DOI":"10.1016\/j.oraloncology.2024.106778","volume":"152","author":"R Megahed","year":"2024","unstructured":"Megahed R, Prabhu AV, Mack DP, Gholami S, Samanta S, Patel M, et al. Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: an institutional series. Oral Oncol. 2024;152:106778. https:\/\/doi.org\/10.1016\/j.oraloncology.2024.106778.","journal-title":"Oral Oncol"},{"key":"4385_CR208","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1001\/jamaoncol.2024.1143","volume":"10","author":"NF Saba","year":"2024","unstructured":"Saba NF, Wong SJ, Nasti T, McCook-Veal AA, McDonald MW, Stokes WA, et al. Intensity-modulated reirradiation therapy with Nivolumab in recurrent or second primary head and neck squamous cell carcinoma: a nonrandomized controlled trial. JAMA Oncol. 2024;10:896. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1143.","journal-title":"JAMA Oncol"},{"key":"4385_CR209","doi-asserted-by":"publisher","first-page":"666515","DOI":"10.3389\/fcell.2021.666515","volume":"9","author":"A Affolter","year":"2021","unstructured":"Affolter A, Lammert A, Kern J, Scherl C, Rotter N. Precision medicine gains momentum: novel 3D models and stem cell-based approaches in head and neck cancer. Front Cell Dev Biol. 2021;9:666515. https:\/\/doi.org\/10.3389\/fcell.2021.666515.","journal-title":"Front Cell Dev Biol"},{"key":"4385_CR210","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.semradonc.2017.08.003","volume":"28","author":"V Gr\u00e9goire","year":"2018","unstructured":"Gr\u00e9goire V, Thorwarth D, Lee JA. Molecular imaging-guided radiotherapy for the treatment of head-and-neck squamous cell carcinoma: Does it fulfill the promises? Semin Radiat Oncol. 2018;28:35\u201345. https:\/\/doi.org\/10.1016\/j.semradonc.2017.08.003.","journal-title":"Semin Radiat Oncol"},{"key":"4385_CR211","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s41199-020-00056-4","volume":"5","author":"I Tinhofer","year":"2020","unstructured":"Tinhofer I, Braunholz D, Klinghammer K. Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers Head Neck. 2020;5:9. https:\/\/doi.org\/10.1186\/s41199-020-00056-4.","journal-title":"Cancers Head Neck"},{"key":"4385_CR212","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3390\/cancers11050616","volume":"11","author":"C Peitzsch","year":"2019","unstructured":"Peitzsch C, Nathansen J, Schniewind SI, Schwarz F, Dubrovska A. Cancer stem cells in head and neck squamous cell carcinoma: identification, characterization and clinical implications. Cancers (Basel). 2019;11:616. https:\/\/doi.org\/10.3390\/cancers11050616.","journal-title":"Cancers (Basel)"},{"key":"4385_CR213","doi-asserted-by":"publisher","first-page":"396076","DOI":"10.1155\/2011\/396076","volume":"2011","author":"N Moore","year":"2011","unstructured":"Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. 2011;2011:396076. https:\/\/doi.org\/10.1155\/2011\/396076.","journal-title":"J Oncol"},{"issue":"1101\u20137","key":"4385_CR214","first-page":"1110","volume":"28","author":"S Dawood","year":"2014","unstructured":"Dawood S, Austin L, Cristofanilli M. Cancer stem cells: implications for cancer therapy. Oncology (Williston Park). 2014;28(1101\u20137):1110.","journal-title":"Oncology (Williston Park)"},{"key":"4385_CR215","doi-asserted-by":"publisher","first-page":"116","DOI":"10.20517\/cdr.2022.107","volume":"6","author":"JM Siqueira","year":"2023","unstructured":"Siqueira JM, Heguedusch D, Rodini CO, Nunes FD, Rodrigues MFSD. Mechanisms involved in cancer stem cell resistance in head and neck squamous cell carcinoma. Cancer Drug Resist. 2023;6:116\u201337. https:\/\/doi.org\/10.20517\/cdr.2022.107.","journal-title":"Cancer Drug Resist"},{"key":"4385_CR216","doi-asserted-by":"publisher","first-page":"658","DOI":"10.21873\/cdp.10378","volume":"4","author":"M Matsuo","year":"2024","unstructured":"Matsuo M, Hashimoto K, Kogo R, Sato M, Manako T, Nakagawa T. Interval to recurrence affects survival in recurrent head and neck squamous cell carcinoma. CDP. 2024;4:658\u201366. https:\/\/doi.org\/10.21873\/cdp.10378.","journal-title":"CDP"},{"key":"4385_CR217","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/jcar.JCar_14_20","volume":"20","author":"P Singh","year":"2021","unstructured":"Singh P, Augustine D, Rao RS, Patil S, Awan KH, Sowmya SV, et al. Role of cancer stem cells in head-and-neck squamous cell carcinoma\u2014a systematic review. J Carcinog. 2021;20:12. https:\/\/doi.org\/10.4103\/jcar.JCar_14_20.","journal-title":"J Carcinog"},{"key":"4385_CR218","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1073\/pnas.0610117104","volume":"104","author":"ME Prince","year":"2007","unstructured":"Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104:973\u20138. https:\/\/doi.org\/10.1073\/pnas.0610117104.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4385_CR219","doi-asserted-by":"publisher","first-page":"5329","DOI":"10.1158\/1078-0432.ccr-10-0799","volume":"16","author":"MC de Jong","year":"2010","unstructured":"de Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res. 2010;16:5329\u201338. https:\/\/doi.org\/10.1158\/1078-0432.ccr-10-0799.","journal-title":"Clin Cancer Res"},{"key":"4385_CR220","doi-asserted-by":"publisher","DOI":"10.3892\/or.2011.1322","author":"A Faber","year":"2011","unstructured":"Faber A. CD44 as a stem cell marker in head and neck squamous cell carcinoma. Oncol Rep. 2011. https:\/\/doi.org\/10.3892\/or.2011.1322.","journal-title":"Oncol Rep"},{"key":"4385_CR221","doi-asserted-by":"publisher","first-page":"696028","DOI":"10.1155\/2014\/696028","volume":"2014","author":"V Bol","year":"2014","unstructured":"Bol V, Gr\u00e9goire V. Biological basis for increased sensitivity to radiation therapy in HPV-positive head and neck cancers. Biomed Res Int. 2014;2014:696028. https:\/\/doi.org\/10.1155\/2014\/696028.","journal-title":"Biomed Res Int"},{"key":"4385_CR222","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-018-0605-5","volume":"11","author":"C Chen","year":"2018","unstructured":"Chen C, Zhao S, Karnad A, Freeman JW. The biology and role of CD44 in cancer progression: therapeutic implications. J Hematol Oncol. 2018;11:64. https:\/\/doi.org\/10.1186\/s13045-018-0605-5.","journal-title":"J Hematol Oncol"},{"key":"4385_CR223","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-020-00192-0","author":"H Xu","year":"2020","unstructured":"Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 2020. https:\/\/doi.org\/10.1186\/s40164-020-00192-0.","journal-title":"Exp Hematol Oncol"},{"key":"4385_CR224","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.18632\/oncotarget.3410","volume":"6","author":"S McFarlane","year":"2015","unstructured":"McFarlane S, Coulter JA, Tibbits P, O\u2019Grady A, McFarlane C, Montgomery N, et al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget. 2015;6:11465\u201376. https:\/\/doi.org\/10.18632\/oncotarget.3410.","journal-title":"Oncotarget"},{"key":"4385_CR225","doi-asserted-by":"publisher","first-page":"11018","DOI":"10.18632\/oncotarget.6920","volume":"7","author":"H Tomita","year":"2016","unstructured":"Tomita H, Tanaka K, Tanaka T, Hara A. Aldehyde dehydrogenase 1A1 in stem cells and cancer. Oncotarget. 2016;7:11018\u201332. https:\/\/doi.org\/10.18632\/oncotarget.6920.","journal-title":"Oncotarget"},{"key":"4385_CR226","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-22220-0","author":"W Li","year":"2018","unstructured":"Li W, Ma H, Zhang J, Zhu L, Wang C, Yang Y. Author correction: unraveling the roles of CD44\/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-22220-0.","journal-title":"Sci Rep"},{"key":"4385_CR227","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1002\/ijc.25927","volume":"129","author":"S Sun","year":"2011","unstructured":"Sun S, Wang Z. Head neck squamous cell carcinoma c\u2010Met+ cells display cancer stem cell properties and are responsible for cisplatin\u2010resistance and metastasis. Int J Cancer. 2011;129:2337\u201348. https:\/\/doi.org\/10.1002\/ijc.25927.","journal-title":"Int J Cancer"},{"key":"4385_CR228","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1089\/scd.2008.0338","volume":"18","author":"Y Wu","year":"2009","unstructured":"Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18:1127\u201334. https:\/\/doi.org\/10.1089\/scd.2008.0338.","journal-title":"Stem Cells Dev"},{"key":"4385_CR229","doi-asserted-by":"publisher","DOI":"10.1172\/jci34401","author":"SV Shmelkov","year":"2008","unstructured":"Shmelkov SV, Butler JM, Hooper AT, Hormigo A, Kushner J, Milde T, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133\u2013 metastatic colon cancer cells initiate tumors. J Clin Invest. 2008. https:\/\/doi.org\/10.1172\/jci34401.","journal-title":"J Clin Invest"},{"key":"4385_CR230","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0110-5","author":"L Yang","year":"2020","unstructured":"Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, et al. Targeting cancer stem cell pathways for cancer therapy. Sig Transduct Target Ther. 2020. https:\/\/doi.org\/10.1038\/s41392-020-0110-5.","journal-title":"Sig Transduct Target Ther"},{"key":"4385_CR231","doi-asserted-by":"publisher","first-page":"36220","DOI":"10.18632\/oncotarget.8811","volume":"7","author":"M Dimri","year":"2016","unstructured":"Dimri M, Kang M, Dimri GP. A miR-200c\/141-BMI1 autoregulatory loop regulates oncogenic activity of BMI1 in cancer cells. Oncotarget. 2016;7:36220\u201334. https:\/\/doi.org\/10.18632\/oncotarget.8811.","journal-title":"Oncotarget"},{"key":"4385_CR232","doi-asserted-by":"publisher","first-page":"609259","DOI":"10.1155\/2011\/609259","volume":"2011","author":"C-C Yu","year":"2011","unstructured":"Yu C-C, Lo W-L, Chen Y-W, Huang P-I, Hsu H-S, Tseng L-M, et al. Bmi-1 regulates Snail expression and promotes metastasis ability in head and neck squamous cancer-derived ALDH1 positive cells. J Oncol. 2011;2011:609259. https:\/\/doi.org\/10.1155\/2011\/609259.","journal-title":"J Oncol"},{"key":"4385_CR233","doi-asserted-by":"publisher","DOI":"10.1038\/srep43008","author":"Z Fan","year":"2017","unstructured":"Fan Z, Li M, Chen X, Wang J, Liang X, Wang H, et al. Prognostic value of cancer stem cell markers in head and neck squamous cell carcinoma: a meta-analysis. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/srep43008.","journal-title":"Sci Rep"},{"key":"4385_CR234","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrclinonc.2015.61","volume":"12","author":"N Takebe","year":"2015","unstructured":"Takebe N, Miele L, Harris PJ, Jeong W, Bando H, Kahn M, et al. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015;12:445\u201364. https:\/\/doi.org\/10.1038\/nrclinonc.2015.61.","journal-title":"Nat Rev Clin Oncol"},{"key":"4385_CR235","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.3389\/fonc.2020.01533","volume":"10","author":"A Espinosa-S\u00e1nchez","year":"2020","unstructured":"Espinosa-S\u00e1nchez A, Su\u00e1rez-Mart\u00ednez E, S\u00e1nchez-D\u00edaz L, Carnero A. Therapeutic targeting of signaling pathways related to cancer stemness. Front Oncol. 2020;10:1533. https:\/\/doi.org\/10.3389\/fonc.2020.01533.","journal-title":"Front Oncol"},{"key":"4385_CR236","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.650772","author":"V Kumar","year":"2021","unstructured":"Kumar V, Vashishta M, Kong L, Wu X, Lu JJ, Guha C, et al. The role of notch, hedgehog, and wnt signaling pathways in the resistance of tumors to anticancer therapies. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.650772.","journal-title":"Front Cell Dev Biol"},{"key":"4385_CR237","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/cells7110208","volume":"7","author":"IN Sari","year":"2018","unstructured":"Sari IN, Phi LTH, Jun N, Wijaya YT, Lee S, Kwon HY. Hedgehog signaling in cancer: a prospective therapeutic target for eradicating cancer stem cells. Cells. 2018;7:208. https:\/\/doi.org\/10.3390\/cells7110208.","journal-title":"Cells"},{"key":"4385_CR238","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.3390\/ijms23031733","volume":"23","author":"NM Nguyen","year":"2022","unstructured":"Nguyen NM, Cho J. Hedgehog pathway inhibitors as targeted cancer therapy and strategies to overcome drug resistance. Int J Mol Sci. 2022;23:1733. https:\/\/doi.org\/10.3390\/ijms23031733.","journal-title":"Int J Mol Sci"},{"key":"4385_CR239","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/14728222.2023.2218613","volume":"27","author":"S Halder","year":"2023","unstructured":"Halder S, Basu S, Lall SP, Ganti AK, Batra SK, Seshacharyulu P. Targeting the EGFR signaling pathway in cancer therapy: What\u2019s new in 2023? Expert Opin Ther Targets. 2023;27:305\u201324. https:\/\/doi.org\/10.1080\/14728222.2023.2218613.","journal-title":"Expert Opin Ther Targets"},{"key":"4385_CR240","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/s41388-020-01564-w","volume":"40","author":"G Kaushik","year":"2021","unstructured":"Kaushik G, Seshacharyulu P, Rauth S, Nallasamy P, Rachagani S, Nimmakayala RK, et al. Selective inhibition of stemness through EGFR\/FOXA2\/SOX9 axis reduces pancreatic cancer metastasis. Oncogene. 2021;40:848\u201362. https:\/\/doi.org\/10.1038\/s41388-020-01564-w.","journal-title":"Oncogene"},{"key":"4385_CR241","doi-asserted-by":"publisher","first-page":"20961","DOI":"10.18632\/oncotarget.15468","volume":"8","author":"MA Macha","year":"2017","unstructured":"Macha MA, Rachagani S, Qazi AK, Jahan R, Gupta S, Patel A, et al. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells. Oncotarget. 2017;8:20961\u201373. https:\/\/doi.org\/10.18632\/oncotarget.15468.","journal-title":"Oncotarget"},{"key":"4385_CR242","doi-asserted-by":"publisher","DOI":"10.3389\/froh.2021.685236","author":"LA Shahoumi","year":"2021","unstructured":"Shahoumi LA. Oral cancer stem cells: therapeutic implications and challenges. Front Oral Health. 2021. https:\/\/doi.org\/10.3389\/froh.2021.685236.","journal-title":"Front Oral Health"},{"key":"4385_CR243","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2478\/bjdm-2021-0012","volume":"25","author":"V Zisis","year":"2021","unstructured":"Zisis V, Venou M, Poulopoulos A, Andreadis D. Cancer stem cells in head and neck squamous cell carcinoma: treatment modalities. Balkan J Dent Med. 2021;25:73\u20139. https:\/\/doi.org\/10.2478\/bjdm-2021-0012.","journal-title":"Balkan J Dent Med"},{"key":"4385_CR244","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1007\/s00262-003-0396-5","volume":"52","author":"DR Colnot","year":"2003","unstructured":"Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, et al. Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2003;52:576\u201382. https:\/\/doi.org\/10.1007\/s00262-003-0396-5.","journal-title":"Cancer Immunol Immunother"},{"key":"4385_CR245","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.stem.2020.06.022","volume":"27","author":"L Jia","year":"2020","unstructured":"Jia L, Zhang W, Wang C-Y. BMI1 inhibition eliminates residual cancer stem cells after PD1 blockade and activates antitumor immunity to prevent metastasis and relapse. Cell Stem Cell. 2020;27:238-253.e6. https:\/\/doi.org\/10.1016\/j.stem.2020.06.022.","journal-title":"Cell Stem Cell"},{"key":"4385_CR246","doi-asserted-by":"publisher","first-page":"113906","DOI":"10.1016\/j.biopha.2022.113906","volume":"156","author":"E Rouzbahani","year":"2022","unstructured":"Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomed Pharmacother. 2022;156:113906. https:\/\/doi.org\/10.1016\/j.biopha.2022.113906.","journal-title":"Biomed Pharmacother"},{"key":"4385_CR247","doi-asserted-by":"publisher","first-page":"e265","DOI":"10.1002\/mco2.265","volume":"4","author":"Z-N Lei","year":"2023","unstructured":"Lei Z-N, Tian Q, Teng Q-X, Wurpel JND, Zeng L, Pan Y, et al. Understanding and targeting resistance mechanisms in cancer. MedComm. 2023;4:e265. https:\/\/doi.org\/10.1002\/mco2.265.","journal-title":"MedComm"},{"key":"4385_CR248","doi-asserted-by":"publisher","first-page":"5098","DOI":"10.3390\/cancers13205098","volume":"13","author":"SE Mudra","year":"2021","unstructured":"Mudra SE, Sadhukhan P, Ugurlu MT, Alam S, Hoque MO. Therapeutic targeting of cancer stem cells in lung, head and neck, and bladder cancers. Cancers. 2021;13:5098. https:\/\/doi.org\/10.3390\/cancers13205098.","journal-title":"Cancers"},{"key":"4385_CR249","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1177\/0022034520965141","volume":"100","author":"T Nakano","year":"2021","unstructured":"Nakano T, Warner KA, Oklejas AE, Zhang Z, Rodriguez-Ramirez C, Shuman AG, et al. mTOR inhibition ablates Cisplatin-resistant salivary gland cancer stem cells. J Dent Res. 2021;100:377\u201386. https:\/\/doi.org\/10.1177\/0022034520965141.","journal-title":"J Dent Res"},{"key":"4385_CR250","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-20345-w","author":"VP Wagner","year":"2018","unstructured":"Wagner VP, Martins MD, Martins MAT, Almeida LO, Warner KA, N\u00f6r JE, et al. Targeting histone deacetylase and NF\u03baB signaling as a novel therapy for mucoepidermoid carcinomas. Sci Rep. 2018. https:\/\/doi.org\/10.1038\/s41598-018-20345-w.","journal-title":"Sci Rep"},{"key":"4385_CR251","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/curroncol32040232","volume":"32","author":"S Sreenivasan","year":"2025","unstructured":"Sreenivasan S, Jiwani RA, White R, Bakalov V, Moll R, Liput J, et al. Advances in targeted and systemic therapy for salivary gland carcinomas: current options and future directions. Curr Oncol. 2025;32:232. https:\/\/doi.org\/10.3390\/curroncol32040232.","journal-title":"Curr Oncol"},{"key":"4385_CR252","doi-asserted-by":"publisher","first-page":"4342","DOI":"10.1200\/JCO.2003.04.190","volume":"21","author":"MC Heinrich","year":"2003","unstructured":"Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.04.190.","journal-title":"J Clin Oncol"},{"key":"4385_CR253","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3390\/molecules26040972","volume":"26","author":"M Ghanbari-Movahed","year":"2021","unstructured":"Ghanbari-Movahed M, Ghanbari-Movahed Z, Momtaz S, Kilpatrick KL, Farzaei MH, Bishayee A. Unlocking the secrets of cancer stem cells with \u03b3-Secretase inhibitors: a novel anticancer strategy. Molecules. 2021;26:972. https:\/\/doi.org\/10.3390\/molecules26040972.","journal-title":"Molecules"},{"key":"4385_CR254","doi-asserted-by":"publisher","first-page":"84594","DOI":"10.18632\/oncotarget.13141","volume":"7","author":"N Mukherjee","year":"2016","unstructured":"Mukherjee N, Almeida A, Partyka KA, Lu Y, Schwan JV, Lambert K, et al. Combining a GSI and BCL-2 inhibitor to overcome melanoma\u2019s resistance to current treatments. Oncotarget. 2016;7:84594\u2013607. https:\/\/doi.org\/10.18632\/oncotarget.13141.","journal-title":"Oncotarget"},{"key":"4385_CR255","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12943-017-0595-x","volume":"16","author":"C Melzer","year":"2017","unstructured":"Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R. Cancer stem cell niche models and contribution by mesenchymal stroma\/stem cells. Mol Cancer. 2017;16:28. https:\/\/doi.org\/10.1186\/s12943-017-0595-x.","journal-title":"Mol Cancer"},{"key":"4385_CR256","doi-asserted-by":"publisher","first-page":"9969","DOI":"10.1158\/0008-5472.CAN-10-1712","volume":"70","author":"S Krishnamurthy","year":"2010","unstructured":"Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, et al. Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 2010;70:9969\u201378. https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-1712.","journal-title":"Cancer Res"},{"key":"4385_CR257","doi-asserted-by":"publisher","DOI":"10.20517\/2574-1209.2023.73","author":"F Nieberle","year":"2024","unstructured":"Nieberle F, Spoerl S, G\u0142uszko A, Taxis J, Spanier G, Erber R, et al. Anti-angiogenic therapy in head and neck squamous cell carcinoma - current limitations and future directions. Vessel Plus. 2024. https:\/\/doi.org\/10.20517\/2574-1209.2023.73.","journal-title":"Vessel Plus"},{"key":"4385_CR258","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12943-025-02265-2","volume":"24","author":"Y Pan","year":"2025","unstructured":"Pan Y, Yuan C, Zeng C, Sun C, Xia L, Wang G, et al. Cancer stem cells and niches: challenges in immunotherapy resistance. Mol Cancer. 2025;24:52. https:\/\/doi.org\/10.1186\/s12943-025-02265-2.","journal-title":"Mol Cancer"},{"key":"4385_CR259","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.ejca.2015.06.115","volume":"51","author":"SA Piha-Paul","year":"2015","unstructured":"Piha-Paul SA, Munster PN, Hollebecque A, Argil\u00e9s G, Dajani O, Cheng JD, et al. Results of a phase 1 trial combining ridaforolimus and MK-0752 in patients with advanced solid tumours. Eur J Cancer. 2015;51:1865\u201373. https:\/\/doi.org\/10.1016\/j.ejca.2015.06.115.","journal-title":"Eur J Cancer"},{"key":"4385_CR260","doi-asserted-by":"publisher","first-page":"4222","DOI":"10.1200\/JCO.2011.37.8893","volume":"29","author":"EA Mroz","year":"2011","unstructured":"Mroz EA, Forastiere AA, Rocco JW. Implications of the oropharyngeal cancer epidemic. J Clin Oncol. 2011;29:4222\u20133. https:\/\/doi.org\/10.1200\/JCO.2011.37.8893.","journal-title":"J Clin Oncol"},{"key":"4385_CR261","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/s41416-019-0602-7","volume":"122","author":"ME Sabatini","year":"2020","unstructured":"Sabatini ME, Chiocca S. Human Papillomavirus as a driver of head and neck cancers. Br J Cancer. 2020;122:306\u201314. https:\/\/doi.org\/10.1038\/s41416-019-0602-7.","journal-title":"Br J Cancer"},{"key":"4385_CR262","doi-asserted-by":"publisher","first-page":"500","DOI":"10.3390\/cells9020500","volume":"9","author":"KC Wai","year":"2020","unstructured":"Wai KC, Strohl MP, van Zante A, Ha PK. Molecular diagnostics in Human Papillomavirus-related head and neck squamous cell carcinoma. Cells. 2020;9:500. https:\/\/doi.org\/10.3390\/cells9020500.","journal-title":"Cells"},{"key":"4385_CR263","doi-asserted-by":"publisher","first-page":"524928","DOI":"10.3389\/fonc.2020.524928","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang H, Zhang Y, Bai W, Wang B, Wei J, Ji R, et al. Feasibility of immunohistochemical p16 staining in the diagnosis of Human Papillomavirus infection in patients with squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Front Oncol. 2020;10:524928. https:\/\/doi.org\/10.3389\/fonc.2020.524928.","journal-title":"Front Oncol"},{"key":"4385_CR264","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s12070-019-01683-1","volume":"71","author":"N Basheeth","year":"2019","unstructured":"Basheeth N, Patil N. Biomarkers in head and neck cancer an update. Indian J Otolaryngol Head Neck Surg. 2019;71:1002\u201311. https:\/\/doi.org\/10.1007\/s12070-019-01683-1.","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"4385_CR265","doi-asserted-by":"publisher","first-page":"1473706","DOI":"10.3389\/fonc.2024.1473706","volume":"14","author":"KS Saini","year":"2024","unstructured":"Saini KS, Somara S, Ko HC, Thatai P, Quintana A, Wallen ZD, et al. Biomarkers in head and neck squamous cell carcinoma: unraveling the path to precision immunotherapy. Front Oncol. 2024;14:1473706. https:\/\/doi.org\/10.3389\/fonc.2024.1473706.","journal-title":"Front Oncol"},{"key":"4385_CR266","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/biomedicines12020415","volume":"12","author":"HW Eberly","year":"2024","unstructured":"Eberly HW, Sciscent BY, Lorenz FJ, Rettig EM, Goyal N. Current and emerging diagnostic, prognostic, and predictive biomarkers in head and neck cancer. Biomedicines. 2024;12:415. https:\/\/doi.org\/10.3390\/biomedicines12020415.","journal-title":"Biomedicines"},{"key":"4385_CR267","doi-asserted-by":"publisher","first-page":"6213","DOI":"10.1200\/JCO.2009.23.1670","volume":"27","author":"W Shi","year":"2009","unstructured":"Shi W, Kato H, Perez-Ordonez B, Pintilie M, Huang S, Hui A, et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol. 2009;27:6213\u201321. https:\/\/doi.org\/10.1200\/JCO.2009.23.1670.","journal-title":"J Clin Oncol"},{"key":"4385_CR268","doi-asserted-by":"publisher","first-page":"559","DOI":"10.5858\/arpa.2017-0286-CP","volume":"142","author":"JS Lewis","year":"2018","unstructured":"Lewis JS, Beadle B, Bishop JA, Chernock RD, Colasacco C, Lacchetti C, et al. Human Papillomavirus testing in head and neck carcinomas: guideline from the College of American Pathologists. Arch Pathol Lab Med. 2018;142:559\u201397. https:\/\/doi.org\/10.5858\/arpa.2017-0286-CP.","journal-title":"Arch Pathol Lab Med"},{"key":"4385_CR269","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0002-9440(10)65689-1","volume":"153","author":"T Sano","year":"1998","unstructured":"Sano T, Oyama T, Kashiwabara K, Fukuda T, Nakajima T. Expression status of p16 protein is associated with Human Papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol. 1998;153:1741\u20138. https:\/\/doi.org\/10.1016\/S0002-9440(10)65689-1.","journal-title":"Am J Pathol"},{"key":"4385_CR270","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1186\/s12879-022-07654-2","volume":"22","author":"C Simoens","year":"2022","unstructured":"Simoens C, Gheit T, Ridder R, Gorbaslieva I, Holzinger D, Lucas E, et al. Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer. BMC Infect Dis. 2022;22:676. https:\/\/doi.org\/10.1186\/s12879-022-07654-2.","journal-title":"BMC Infect Dis"},{"key":"4385_CR271","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/978-3-030-63234-2_12","volume-title":"Critical Issues in Head and Neck Oncology","author":"S Gkolfinopoulos","year":"2021","unstructured":"Gkolfinopoulos S, Economopoulou P, Psyrri A. Prognostic role of p16\/HPV in non-oropharyngeal head and neck squamous cell cancer (HNSCC). In: Vermorken JB, Budach V, Leemans CR, Machiels J-P, Nicolai P, O\u2019Sullivan B, editors. Critical Issues in Head and Neck Oncology. Cham: Springer International Publishing; 2021. p. 181\u201392."},{"key":"4385_CR272","doi-asserted-by":"publisher","first-page":"100177","DOI":"10.1016\/j.clinsp.2023.100177","volume":"78","author":"B Gutic","year":"2023","unstructured":"Gutic B, Bozanovic T, Mandic A, Dugalic S, Todorovic J, Stanisavljevic D, et al. Programmed cell death-1 and its ligands: current knowledge and possibilities in immunotherapy. Clinics (Sao Paulo). 2023;78:100177. https:\/\/doi.org\/10.1016\/j.clinsp.2023.100177.","journal-title":"Clinics (Sao Paulo)"},{"key":"4385_CR273","doi-asserted-by":"publisher","first-page":"153605","DOI":"10.1016\/j.prp.2021.153605","volume":"226","author":"G Paolino","year":"2021","unstructured":"Paolino G, Pantanowitz L, Barresi V, Pagni F, Munari E, Moretta L, et al. PD-L1 evaluation in head and neck squamous cell carcinoma: insights regarding specimens, heterogeneity and therapy. Pathol Res Pract. 2021;226:153605. https:\/\/doi.org\/10.1016\/j.prp.2021.153605.","journal-title":"Pathol Res Pract"},{"key":"4385_CR274","doi-asserted-by":"publisher","first-page":"e70274","DOI":"10.1002\/mco2.70274","volume":"6","author":"P Gao","year":"2025","unstructured":"Gao P, Li X, Duan Z, Wang Y, Li Y, Wang J, et al. Improvement of the anticancer efficacy of PD-1\/PD-L1 blockade: advances in molecular mechanisms and therapeutic strategies. MedComm. 2025;6:e70274. https:\/\/doi.org\/10.1002\/mco2.70274.","journal-title":"MedComm"},{"key":"4385_CR275","doi-asserted-by":"publisher","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","volume":"34","author":"LQM Chow","year":"2016","unstructured":"Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, et al. Antitumor activity of Pembrolizumab in biomarker-unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort. J Clin Oncol. 2016;34:3838\u201345. https:\/\/doi.org\/10.1200\/JCO.2016.68.1478.","journal-title":"J Clin Oncol"},{"key":"4385_CR276","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","volume":"17","author":"K Muro","year":"2016","unstructured":"Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17:717\u201326. https:\/\/doi.org\/10.1016\/S1470-2045(16)00175-3.","journal-title":"Lancet Oncol"},{"key":"4385_CR277","doi-asserted-by":"publisher","first-page":"3047","DOI":"10.2147\/OTT.S196252","volume":"13","author":"MG McCusker","year":"2020","unstructured":"McCusker MG, Orkoulas-Razis D, Mehra R. Potential of Pembrolizumab in metastatic or recurrent head and neck cancer: evidence to date. OTT. 2020;13:3047\u201359. https:\/\/doi.org\/10.2147\/OTT.S196252.","journal-title":"OTT"},{"key":"4385_CR278","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/cam4.4722","volume":"11","author":"C Chalker","year":"2022","unstructured":"Chalker C, Voutsinas JM, Wu QV, Santana\u2010Davila R, Hwang V, Baik CS, et al. Performance status ( PS ) as a predictor of poor response to immune checkpoint inhibitors ( ICI ) in recurrent\/metastatic head and neck cancer ( RMHNSCC ) patients. Cancer Med. 2022;11:4104\u201311. https:\/\/doi.org\/10.1002\/cam4.4722.","journal-title":"Cancer Med"},{"key":"4385_CR279","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1007\/s00520-012-1386-y","volume":"20","author":"GTB Corr\u00eaa","year":"2012","unstructured":"Corr\u00eaa GTB, Bandeira GA, Cavalcanti BG, Santos FBG, Neto JFR, Guimar\u00e3es ALS, et al. Analysis of ECOG performance status in head and neck squamous cell carcinoma patients: association with sociodemographical and clinical factors, and overall survival. Support Care Cancer. 2012;20:2679\u201385. https:\/\/doi.org\/10.1007\/s00520-012-1386-y.","journal-title":"Support Care Cancer"},{"key":"4385_CR280","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","volume":"145","author":"FG Dall\u2019Olio","year":"2020","unstructured":"Dall\u2019Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A. ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors\u2014a systematic review and meta-analysis of real world data. Lung Cancer. 2020;145:95\u2013104. https:\/\/doi.org\/10.1016\/j.lungcan.2020.04.027.","journal-title":"Lung Cancer"},{"key":"4385_CR281","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1111\/cas.14590","volume":"111","author":"H Kano","year":"2020","unstructured":"Kano H, Ichihara E, Harada D, Inoue K, Kayatani H, Hosokawa S, et al. Utility of immune checkpoint inhibitors in non\u2010small\u2010cell lung cancer patients with poor performance status. Cancer Sci. 2020;111:3739\u201346. https:\/\/doi.org\/10.1111\/cas.14590.","journal-title":"Cancer Sci"},{"key":"4385_CR282","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1002\/cncr.32782","volume":"126","author":"LA Petrillo","year":"2020","unstructured":"Petrillo LA, El\u2010Jawahri A, Nipp RD, Lichtenstein MRL, Durbin SM, Reynolds KL, et al. Performance status and end\u2010of\u2010life care among adults with non\u2013small cell lung cancer receiving immune checkpoint inhibitors. Cancer. 2020;126:2288\u201395. https:\/\/doi.org\/10.1002\/cncr.32782.","journal-title":"Cancer"},{"key":"4385_CR283","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00520-009-0681-8","volume":"18","author":"G Capuano","year":"2010","unstructured":"Capuano G, Gentile PC, Bianciardi F, Tosti M, Palladino A, Di Palma M. Prevalence and influence of malnutrition on quality of life and performance status in patients with locally advanced head and neck cancer before treatment. Support Care Cancer. 2010;18:433\u20137. https:\/\/doi.org\/10.1007\/s00520-009-0681-8.","journal-title":"Support Care Cancer"},{"key":"4385_CR284","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/hed.10092","volume":"24","author":"BR Pauloski","year":"2002","unstructured":"Pauloski BR, Rademaker AW, Logemann JA, Lazarus CL, Newman L, Hamner A, et al. Swallow function and perception of dysphagia in patients with head and neck cancer. Head Neck. 2002;24:555\u201365. https:\/\/doi.org\/10.1002\/hed.10092.","journal-title":"Head Neck"},{"key":"4385_CR285","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0936-6555(03)00155-9","volume":"15","author":"P Ravasco","year":"2003","unstructured":"Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Nutritional deterioration in cancer: the role of disease and diet. Clin Oncol. 2003;15:443\u201350. https:\/\/doi.org\/10.1016\/S0936-6555(03)00155-9.","journal-title":"Clin Oncol"},{"key":"4385_CR286","doi-asserted-by":"publisher","first-page":"6802","DOI":"10.3390\/jcm14196802","volume":"14","author":"Y Zhu","year":"2025","unstructured":"Zhu Y, Diao W, Zhu X, Yu S, Xia X, Han W, et al. Impact of smoking on outcomes in HPV-positive oropharyngeal squamous cell carcinoma in a Chinese cohort under AJCC 8th Edition Staging. J Clin Med. 2025;14:6802. https:\/\/doi.org\/10.3390\/jcm14196802.","journal-title":"J Clin Med"},{"key":"4385_CR287","doi-asserted-by":"publisher","first-page":"e2245818","DOI":"10.1001\/jamanetworkopen.2022.45818","volume":"5","author":"SJ Ma","year":"2022","unstructured":"Ma SJ, Yu H, Yu B, Waldman O, Khan M, Chatterjee U, et al. Association of pack-years of cigarette smoking with survival and tumor progression among patients treated with chemoradiation for head and neck cancer. JAMA Netw Open. 2022;5:e2245818. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.45818.","journal-title":"JAMA Netw Open"},{"key":"4385_CR288","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1056\/NEJM199301213280302","volume":"328","author":"GP Browman","year":"1993","unstructured":"Browman GP, Wong G, Hodson I, Sathya J, Russell R, McAlpine L, et al. Influence of cigarette smoking on the efficacy of radiation therapy in head and neck cancer. N Engl J Med. 1993;328:159\u201363. https:\/\/doi.org\/10.1056\/NEJM199301213280302.","journal-title":"N Engl J Med"},{"key":"4385_CR289","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ijrobp.2009.10.050","volume":"79","author":"AM Chen","year":"2011","unstructured":"Chen AM, Chen LM, Vaughan A, Sreeraman R, Farwell DG, Luu Q, et al. Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys. 2011;79:414\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.10.050.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4385_CR290","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.ijrobp.2008.09.021","volume":"74","author":"A Fortin","year":"2009","unstructured":"Fortin A, Wang CS, Vigneault \u00c9. Influence of smoking and alcohol drinking behaviors on treatment outcomes of patients with squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys. 2009;74:1062\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.09.021.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4385_CR291","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/lary.26083","volume":"126","author":"AJ Platek","year":"2016","unstructured":"Platek AJ, Jayaprakash V, Merzianu M, Platek ME, Cohan DM, Hicks WL, et al. Smoking cessation is associated with improved survival in oropharynx cancer treated by chemoradiation. Laryngoscope. 2016;126:2733\u20138. https:\/\/doi.org\/10.1002\/lary.26083.","journal-title":"Laryngoscope"},{"key":"4385_CR292","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-T\u00e2n PF, et al. Human Papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363:24\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0912217.","journal-title":"N Engl J Med"},{"key":"4385_CR293","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1200\/JCO.20.03128","volume":"39","author":"SS Yom","year":"2021","unstructured":"Yom SS, Torres-Saavedra P, Caudell JJ, Waldron JN, Gillison ML, Xia P, et al. Reduced-dose radiation therapy for HPV-associated oropharyngeal carcinoma (NRG Oncology HN002). JCO. 2021;39:956\u201365. https:\/\/doi.org\/10.1200\/JCO.20.03128.","journal-title":"JCO"},{"key":"4385_CR294","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1002\/cncr.32849","volume":"126","author":"JR Broughman","year":"2020","unstructured":"Broughman JR, Xiong DD, Moeller BJ, Contrera KJ, Prendes BL, Lamarre ED, et al. Rethinking the 10\u2010pack\u2010year rule for favorable human papillomavirus\u2013associated oropharynx carcinoma: a multi\u2010institution analysis. Cancer. 2020;126:2784\u201390. https:\/\/doi.org\/10.1002\/cncr.32849.","journal-title":"Cancer"},{"key":"4385_CR295","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.radonc.2012.01.011","volume":"103","author":"CM Hoff","year":"2012","unstructured":"Hoff CM, Grau C, Overgaard J. Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma\u2014a prospective study. Radiother Oncol. 2012;103:38\u201344. https:\/\/doi.org\/10.1016\/j.radonc.2012.01.011.","journal-title":"Radiother Oncol"},{"key":"4385_CR296","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.21873\/anticanres.14069","volume":"40","author":"F Simon","year":"2020","unstructured":"Simon F, Schwenk-Zieger S, Becker S, Unger K, Gires O, Baumeister P. Cigarette smoke reduces the efficacy of Cisplatin in head and neck cancer cells\u2014role of ABCG2. Anticancer Res. 2020;40:1277\u201384. https:\/\/doi.org\/10.21873\/anticanres.14069.","journal-title":"Anticancer Res"},{"key":"4385_CR297","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/1097-0142(20010915)92:6<1484::AID-CNCR1473>3.0.CO;2-W","volume":"92","author":"PA Groome","year":"2001","unstructured":"Groome PA, Schulze KM, Mackillop WJ, Grice B, Goh C, Cummings BJ, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer. 2001;92:1484\u201394. https:\/\/doi.org\/10.1002\/1097-0142(20010915)92:6%3c1484::AID-CNCR1473%3e3.0.CO;2-W.","journal-title":"Cancer"},{"key":"4385_CR298","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1158\/1078-0432.CCR-19-1769","volume":"26","author":"JV de la Iglesia","year":"2020","unstructured":"de la Iglesia JV, Slebos RJC, Martin-Gomez L, Wang X, Teer JK, Tan AC, et al. Effects of tobacco smoking on the tumor immune microenvironment in head and neck squamous cell carcinoma. Clin Cancer Res. 2020;26:1474\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1769.","journal-title":"Clin Cancer Res"},{"key":"4385_CR299","doi-asserted-by":"publisher","first-page":"2306257","DOI":"10.1002\/smll.202306257","volume":"20","author":"C Li","year":"2024","unstructured":"Li C, Wang M, Li P, Sheng J, Fu Q. Construction of smart DNA\u2010based drug delivery systems for cancer therapy. Small. 2024;20:2306257. https:\/\/doi.org\/10.1002\/smll.202306257.","journal-title":"Small"},{"issue":"1","key":"4385_CR300","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.apsb.2020.09.016","volume":"11","author":"H Duan","year":"2021","unstructured":"Duan H, Liu Y, Gao Z, Huang W. Recent advances in drug delivery systems for targeting cancer stem cells. Acta Pharm Sin B. 2021;11(1):55\u201370.","journal-title":"Acta Pharm Sin B."},{"key":"4385_CR301","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1016\/j.apsb.2021.09.030","volume":"12","author":"E Rioja-Blanco","year":"2022","unstructured":"Rioja-Blanco E, Arroyo-Solera I, \u00c1lamo P, Casanova I, Gallardo A, Unzueta U, et al. Self-assembling protein nanocarrier for selective delivery of cytotoxic polypeptides to CXCR4+ head and neck squamous cell carcinoma tumors. Acta Pharmaceutica Sinica B. 2022;12:2578\u201391. https:\/\/doi.org\/10.1016\/j.apsb.2021.09.030.","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"4385_CR302","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.actbio.2024.07.024","volume":"185","author":"H Jiang","year":"2024","unstructured":"Jiang H, Xia W, Xia T, Jiang L, Yu J, Zhu X, et al. Chemotactic recruitment of genetically engineered cell membrane-camouflaged metal\u2212organic framework nanoparticles for ischemic osteonecrosis treatment. Acta Biomaterialia. 2024;185:410\u201328. https:\/\/doi.org\/10.1016\/j.actbio.2024.07.024.","journal-title":"Acta Biomaterialia"},{"key":"4385_CR303","doi-asserted-by":"publisher","first-page":"4829","DOI":"10.1038\/s41467-022-31859-3","volume":"13","author":"M Goldberg","year":"2022","unstructured":"Goldberg M, Manzi A, Birdi A, Laporte B, Conway P, Cantin S, et al. A nanoengineered topical transmucosal cisplatin delivery system induces anti-tumor response in animal models and patients with oral cancer. Nat Commun. 2022;13:4829. https:\/\/doi.org\/10.1038\/s41467-022-31859-3.","journal-title":"Nat Commun"},{"key":"4385_CR304","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/pharmaceutics15051327","volume":"15","author":"K D\u017caman","year":"2023","unstructured":"D\u017caman K, Czerwaty K. Extracellular vesicle-based drug delivery systems for head and neck squamous cell carcinoma: a systematic review. Pharmaceutics. 2023;15:1327. https:\/\/doi.org\/10.3390\/pharmaceutics15051327.","journal-title":"Pharmaceutics"},{"key":"4385_CR305","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.3390\/pharmaceutics15071844","volume":"15","author":"A Hariharan","year":"2023","unstructured":"Hariharan A, Tran SD. Localized drug delivery systems: an update on treatment options for head and neck squamous cell carcinomas. Pharmaceutics. 2023;15:1844. https:\/\/doi.org\/10.3390\/pharmaceutics15071844.","journal-title":"Pharmaceutics"},{"key":"4385_CR306","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.actbio.2022.09.027","volume":"153","author":"Y-L Lo","year":"2022","unstructured":"Lo Y-L, Lin H-C, Tseng W-H. Tumor pH-functionalized and charge-tunable nanoparticles for the nucleus\/cytoplasm-directed delivery of oxaliplatin and miRNA in the treatment of head and neck cancer. Acta Biomater. 2022;153:465\u201380. https:\/\/doi.org\/10.1016\/j.actbio.2022.09.027.","journal-title":"Acta Biomater"},{"key":"4385_CR307","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jconrel.2023.11.057","volume":"365","author":"C Yang","year":"2024","unstructured":"Yang C, Xue Y, Duan Y, Mao C, Wan M. Extracellular vesicles and their engineering strategies, delivery systems, and biomedical applications. J Control Release. 2024;365:1089\u2013123. https:\/\/doi.org\/10.1016\/j.jconrel.2023.11.057.","journal-title":"J Control Release"},{"key":"4385_CR308","doi-asserted-by":"publisher","first-page":"189230","DOI":"10.1016\/j.bbcan.2024.189230","volume":"1880","author":"Y Wang","year":"2025","unstructured":"Wang Y, Han J, Zhu Y, Huang N, Qu N. New advances in the therapeutic strategy of head and neck squamous cell carcinoma: a review of latest therapies and cutting-edge research. Biochimica et Biophysica Acta (BBA) Rev Cancer. 2025;1880:189230. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189230.","journal-title":"Biochimica et Biophysica Acta (BBA) Rev Cancer"},{"key":"4385_CR309","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.jconrel.2023.09.037","volume":"363","author":"W Meng","year":"2023","unstructured":"Meng W, Wang L, Du X, Xie M, Yang F, Li F, et al. Engineered mesenchymal stem cell-derived extracellular vesicles constitute a versatile platform for targeted drug delivery. J Control Release. 2023;363:235\u201352. https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.037.","journal-title":"J Control Release"},{"key":"4385_CR310","doi-asserted-by":"publisher","first-page":"2210787","DOI":"10.1002\/adma.202210787","volume":"35","author":"Y Wu","year":"2023","unstructured":"Wu Y, Chang X, Yang G, Chen L, Wu Q, Gao J, et al. A physiologically responsive nanocomposite hydrogel for treatment of head and neck squamous cell carcinoma via proteolysis\u2010targeting chimeras enhanced immunotherapy. Adv Mater. 2023;35:2210787. https:\/\/doi.org\/10.1002\/adma.202210787.","journal-title":"Adv Mater"},{"key":"4385_CR311","doi-asserted-by":"publisher","first-page":"2411032","DOI":"10.1002\/advs.202411032","volume":"12","author":"R Masarwy","year":"2025","unstructured":"Masarwy R, Breier D, Stotsky\u2010Oterin L, Ad\u2010El N, Qassem S, Naidu GS, et al. Targeted CRISPR\/Cas9 lipid nanoparticles elicits therapeutic genome editing in head and neck cancer. Adv Sci. 2025;12:2411032. https:\/\/doi.org\/10.1002\/advs.202411032.","journal-title":"Adv Sci"},{"key":"4385_CR312","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s10895-025-04452-2","volume":"36","author":"A Alsuraifi","year":"2025","unstructured":"Alsuraifi A, Mouzan MM, Algzaare A, Aqeel Z, Al-Essa UI, Mohammed RNA, et al. Quantum dots: catalysts for a new era of precision medicine and biomedical innovation. J Fluoresc. 2025;36:257\u2013320. https:\/\/doi.org\/10.1007\/s10895-025-04452-2.","journal-title":"J Fluoresc"},{"key":"4385_CR313","doi-asserted-by":"publisher","first-page":"9627","DOI":"10.2147\/IJN.S276153","volume":"15","author":"X Zhang","year":"2020","unstructured":"Zhang X, Li H, Yi C, Chen G, Li Y, Zhou Y, et al. Host immune response triggered by graphene quantum-dot-mediated photodynamic therapy for oral squamous cell carcinoma. IJN. 2020;15:9627\u201338. https:\/\/doi.org\/10.2147\/IJN.S276153.","journal-title":"IJN"},{"key":"4385_CR314","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1001\/jamaoto.2025.4766","volume":"152","author":"JJ Huang","year":"2026","unstructured":"Huang JJ, Reznik AS, Sonis S, Franzmann EJ, Villa A. Clinical trial termination or withdrawal in head and neck squamous cell carcinoma. JAMA Otolaryngol Head Neck Surg. 2026;152:242. https:\/\/doi.org\/10.1001\/jamaoto.2025.4766.","journal-title":"JAMA Otolaryngol Head Neck Surg"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04385-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04385-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:41:22Z","timestamp":1790160082000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04385-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":314,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["4385"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04385-7","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}